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I Introduction 
I.1 Catecholamines 
  Catecholamines (dopamine, norepinephrine and epinephrine) are physiologically 
important as they are involved in a number of body functions and also act as 
neurotransmitters. Dopamine acts as a very important neurotransmitter in various 
processes in the central nervous system (CNS). It is also an active player in kidney 
function and also Norepinephrine acts as a neurotransmitter in the CNS and of 
postganglionic sympathetic neurons. Epinephrine is a hormone released from the 
adrenal gland and also serves as neurotransmitter of brainstem neurons (Kuhar et al., 
2006). 
I.1.1 Chemical structure 
The peculiarity of catecholamines is having an amine group, and a nucleus made 
of a catechol ring (a benzene ring with two attached hydroxyl groups), thus they are 
called “catecholamines” (Feldman et al. 1997). 
I.1.2 Catecholamine biosynthesis 
Catecholamines are synthesized from a single precursor, tyrosine, a non-
essential amino acid (Fig. 1). Catecholamine synthesis was first described by Blaschko 
in 1939. Later, tyrosine hydroxylase (TH) was characterized as mediating the rate 
limiting enzymatic step of the synthesis pathway (Nagatsu et al., 1964). The first 
enzymatic step in the catecholamine synthesis is catalyzed by TH, also known as 
tyrosine 3-monooxygenase. It catalyzes the conversion of tyrosine into L-3,4-
dihydroxyphenylalanine (L-DOPA). This enzymatic step is the rate limiting enzymatic 
step of the catecholamine synthesis pathway. Tetrahydrobiopterin, iron and molecular 
oxygen act as cofactors for the activity of this enzyme. The next step is the conversion 
of L-DOPA into dopamine, which is catalyzed by L-aromatic amino acid decarboxylase 
(AADC) also known as dopa decarboxylase (DDC). Pyridoxal phosphate acts as a 
cofactor for this enzyme (Feldman et al. 1997). The next enzymatic step is catalyzed by 
dopamine--hydroxylase (DH), a copper containing soluble and membrane bound 
enzyme (Wallace et al., 1973), which converts dopamine into noradrenaline or 
norepinephrine (NE). Ascorbate and molecular oxygen act as cofactors for this enzyme 
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(Fig. 1). The last enzymatic step of this pathway is catalyzed by phenylethanolamine-N-
methyltransferase (PNMT), which converts norepinephrine (NE) = noradrenaline into 
epinephrine (E) = adrenaline by adding a methyl group to the amino group. S-
adenosylmethionine acts as cofactor for the enzymatic activity (Kuhar et al., 2006; 
Kvetnanský et al., 2009). 
 
Fig. 1: Schematic diagram of catecholamine biosynthesis pathway and its enzymatic 
steps.  
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I.1.3 Characteristics of catecholamine synthesizing enzymes 
TH is a hetrodimeric enzyme; each subunit has a molecular weight of about 60 
kDa. It is a soluble enzyme, various cytoplasmic metabolites or substances can 
modulate the activity of TH, e.g. phosphatidylserine, polyanions and heparin sulfate. 
Analogs of tyrosine, e.g. -methyl-p-tyrosine, act as competitive inhibitors for the TH 
activity. Primarily, it converts tyrosine to L-DOPA but it can also catalyze the 
conversion of phenylalanine to tyrosine (Kuhar et al., 2006). 
DDC is the final enzymatic step in the dopamine synthesizing neuron in the 
CNS. It is of clinical significance in patients suffering from Parkinson disease. The 
patients are given excess of L-DOPA to increase the dopamine synthesis in surviving 
dopaminergic nerve terminals. -Methyldopa is a potent inhibitor of its enzymatic 
activity. DH is a tetrameric glycoprotein consisting of 77 and 73 kDa subunits. This 
enzyme is mainly confined to the inner membrane of vesicles although a minor amount 
is also present freely within the vesicles. This enzyme is also released along with 
norepinephrine from the nerve endings or from the adrenal gland and it is present in 
plasma (Kuhar et al., 2006). PNMT is the terminal enzyme of catecholamine synthesis 
pathway, which is mainly present in the endocrine cells of the adrenal medulla but also 
in some brainstem neurons. The enzyme activity is affected by corticosteroids in the 
adrenal gland and in superior cervical ganglia (Bohn et al., 1984). 
I.2 Non-neuronal catecholamine synthesis 
It has been reported that catecholamine synthesis is not confined to neurons and 
the adrenal gland. Instead, other cells/tissues in the body also express the entire or parts 
of the enzymatic machinery involved in catecholamine synthesis. This non-neuronal 
catecholamine synthesis is of particular interest in various body functions such as in 
immune response, renal function and regulation of vascular tone. 
Recently, catecholamine synthesis in adipocytes has been reported. Vargovic et 
al., 2011 has reported that adipocytes from various body parts posses all the required 
enzymatic machinery to sysnthesize de novo catecholamines (Vargovic et al., 2011). 
Certain cells of immune system, e.g. lymphocytes, can synthesize 
catecholamines de novo and also store them (Bergquist et al., 1994; Musso et al., 1996). 
Recently, Flierl et al. (2007) have shown that alveolar macrophages and blood 
neutrophils are capable of de novo catecholamine synthesis. Expression levels of 
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mRNAs for TH and DH mRNA are upregulated in these cells after exposure to 
lipopolysaccharide (LPS) for 4 h. TH mRNA expression is reported in rat spleen, which 
is another non-neuronal site of catecholamine synthesis, and the catecholamines 
synthesized in spleen are involved in immune response (Kubovcáková et al., 2001). 
Furthermore, it is also reported that catecholamiens and their metabolites are present in 
lymphocytes, where they might modulate the function of T cells and B cells (Bergquist 
et al., 1994). The presence of DDC is also reported in kidney, liver and spleen 
(Lovenberg et al., 1962; Rahman et al., 1981; Lindström and Sehlin, 1983; Adam et al., 
1986). Human peripheral leukocytes express functionally active DDC, which is able to 
convert L-DOPA into dopamine (Kokkinou et al., 2009).   
PNMT mRNA expression has been reported in rat spleen and thymus (Andreassi 
II et al., 1998), in rat lung (Kennedy et al., 1993), and during rat embryonic 
development it is mainly present in the heart (Ebert et al., 1996). Ziegler and coworkers 
have reported non-adrenal PNMT enzymatic activity in various rat tissues such as 
hypothalamus, brain stem, heart, eyelid, muscle and kidney. The activity level in 
various tissues from rat is reported to be hypothalamus  atria  brain stem  ventricle  
eyelid  muscle  kidney (Ziegler et al., 2002). PNMT expression and enzyme activity 
have also been detected in various human organs such as lung, kidney, heart, liver, 
spleen and pancreas. Nonspecific N-methyl transferase (NMT) is also reported in 
various human organs (Kennedy et al., 1995). 
Endocrine and exocrine cells of the rat pancreas can also synthesize and release 
the catecholamine dopamine. Following chemical sympathectomy, TH presence is 
reported in rat pancreas (Mezey et al., 1996). Furthermore, Kawamura and coworkers 
reported TH mRNA expression and enzyme activity in rat aorta, vas deferens and lung. 
Chemical sympathectomy studies with 6-hydroxydopamine showed persistence of 
dopamine and TH activity in aorta, vas deferens, stomach and lung, suggesting a non-
neuronal synthesis of dopamine and possibly other catecholamines in these organs 
(Kawamura et al., 1999).  
Non-neuronal catecholamine (NE and E) synthesis in the rat kidney was 
reported by Silva et al., in 1979 using the isolated perfused kidney model. Proximal 
tubular cells of the kidney were also reported to synthesize dopamine (Chan 1976). 
DiMarco et al., in 2007 have shown synthesis and release of all catecholamines from 
various kidney epithelial cell lines, e.g. LLC-Pk1, MDCK and mIMCD-3. These renal 
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epithelial cell lines express the enzymatic machinery for catecholamine synthesis and 
they are also able to release these catecholamines (DiMarco et al., 2007). 
I.3 Vascular effects of catecholamines 
I.3.1 Vascular effects of dopamine 
Dopamine is profoundly involved in the regulation of blood pressure, sodium 
balance, kidney and adrenal gland function, and is considered to be involved in the 
pathogenesis of hypertension (Hussain and Lokhandwala, 1998; Jose et al., 1998; 
Muhlbauer et al., 2000; Jose et al., 2002). Dopamine has vasodilator effects in the 
systemic circulation. Injecting dopamine in the dog renal artery causes vasodilation 
(McNay et al., 1965), and similar effects were observed in humans (McDonald et al., 
1964). This vasodilator effect in arteries differs from that of NE and E as it cannot be 
blocked by -adrenergic antagonists (McNay and Goldberg, 1966). Dopaminergic 
vasodilation is mediated by specific dopamine receptors. The first evidence for such 
vascular dopamine receptors was provided by Goldberg et al. in 1978 (Goldberg et al., 
1978). Later on it was shown that specific dopamine receptors are present in the 
vasculature of canine paw pads, dopamine released from nerve terminals causes 
vasodilation, and this response is independent from adrenergic receptors (Bell and 
Stubbs, 1978).  
In arteries, presence of D1-like receptors (D1 and D3) is well reported on smooth 
muscle cells of arteries and they mediate a vasodilator response (Hussain and 
Lokhandwala, 2003). D2-like receptors are localized prejunctionally in arteries, and 
stimulation of these receptors inhibits the release of NE, thereby augmenting the 
vasodilator effect of D1-like receptors (Goldberg et al., 1978; Lokhandwala and Hegde, 
1990). D2 and D4 receptors have also been reported to be localized in human and rat 
heart atria (Ricci et al., 1998).  
In the kidney dopamine plays an important role by regulating the sodium 
excretion, increasing diuresis and vasodilation, resulting in reduced  renal resistance 
(Bello-Reuss et al., 1982; Lokhandwala and Hegde, 1990; Ricci et al., 1993). D2 
receptors present in kidney cause vasodilatation by reducing the sympathetic 
vasoconstrictor effect (Rump and Schollmeyer, 1993; Cheung and Barrington, 1996). 
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I.3.2 Structure and types of dopamine receptors 
On the basis of pharmacological properties dopamine receptors were first 
classified in two types: D1 (dopamine is required in micro-molar concentration) and D2 
(dopamine is required in nano-molar concentration) receptors (Goldberg et al., 1978; 
Kebabian and Calne, 1979). The D1 receptor is highly expressed in the brain (Derray et 
al., 1990; Fremeau et al., 1991; Weiner et al., 1991).  
In the canine circulatory system, initial findings suggested that arterial blood 
pressure, heart rate and blood flow in the renal and femoral arteries are regulated by 
dopamine receptors D1 and D2. In another classification scheme, the dopamine receptors 
were classified on the basis of their location: Postjunctional D1 receptors are involved in 
direct vasodilation in the renal artery, and the prejunctional D2 receptors on the 
postganglionic sympathetic nerve terminals have an inhibitory effect on the 
norepinephrine release, which augments vasodilation mediated by the D1 receptor in the 
femoral artery and also results in decreased cardiac contraction (Goldberg et al., 1978). 
Pharmacological studies suggested that, in blood vessels, the D1 receptor is 
predominantly localized in the tunica media (middle layer), which mainly comprises of 
smooth muscle cells. In contrast, D2 receptors are mainly present on sympathetic nerve 
endings and are involved in inhibition of NE release. In the kidney, D1 receptors are 
ubiquitously localized and are involved in regulation of various kidney functions. D2 
receptors are also localized in kidney (Missale et al., 1998). 
Dopamine receptors have seven transmembrane domains and are members of the 
G-protein coupled receptor family. Based on molecular cloning and pharmacologic 
studies, dopamine receptors are classified in two different groups: the D1-like, which 
consists of subtypes D1 and D3, and the D2-like, consisting of subtypes D2, D4 and D5 
(Vallone et al., 2000).  
I.3.3 Vascular effects of norepinephrine and epinephrine 
Norepinephrine is the predominant catecholamine in the arteries of rat and rabbit 
(Head et al., 1982). Both NE and E cause vasoconstriction in canine coronary arteries 
(Berne, 1958). These effects are mediated by adrenergic receptors which are also G-
protein coupled receptors with 7 transmembrane domains. There are two main groups of 
adrenergic receptors first explained by Ahlquist in 1948,  and , which are further 
subdivided. 
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 I.3.4 -Adrenergic receptors 
-Adrenergic receptors are further subdivided into 1 and 2, which are 
involved in various functions; among them are vasoconstriction of coronary arteries 
(Woodman and Vatner, 1987), vasoconstriction of veins (Elliott, 1997) and decreased 
motility of smooth muscle cells in gastrointestinal tract (Sagrada et al., 1987). They are 
distributed overall in the body (Kuhar et al., 2006). 
I.3.5 -Adrenergic receptors  
-Adrenergic receptors are widely distributed in the body and play a major role 
for maintaining homeostasis in the CNS and in cardiovascular, pulmonary and 
endocrine systems (Brodde, 2008). There are three types of -adrenergic receptors: 1, 
2 and 3. In human, 1 is localized in heart, kidney, cerebral cortex and hypothalamus, 
2 is localized in lung, liver, cerebellum, hippocampus, cerebral cortex, smooth muscles 
and olfactory bulb, while 3 is localized in fat tissue and brain (Kuhar et al., 2006).  
I.4 Oxygen sensing, hypoxia and gene regulation  
Oxygen is an essential molecule for all higher organisms, since it is the main 
terminal electron acceptor in mitochondrial oxidative phosphorylation. It also acts as 
substrate or cofactor for various metabolic enzymes. It is necessary that O2 supply must 
be regulated. Any kind of changes (hypoxia, hyperoxia) causes alterations in the cellular 
and tissue metabolism. All the cells of the body are able to detect and respond to 
changes in O2 in their microenvironment. A reduced supply of O2 to tissue or cell causes 
major pathological changes, such as stroke or myocardial infarction. All the higher 
organisms have developed mechanism to cope with low supply of O2. Hypoxia is 
defined as a condition where oxygen demand for steady state cell metabolism is higher 
than oxygen supply. Such exposure to lowered pO2 results in a specific regulation of the 
cellular transcription machinery. Hypoxia can arise in a variety of developmental, 
physiological, and pathological states. Different tissues and organs of the mammalian 
body behave differently in response to acute (seconds to minutes) and chronic (hours to 
days) hypoxia. Acute response usually involves hyperventilation, increased cardiac 
output, vasodilation in systemic arteries, pulmonary vasoconstriction and activation of 
glucose uptake by cells to enhance energy production. In most of tissues, chronic 
8 
 
hypoxia effects erythropoiesis, angiogenesis and neovascularization, tissue remodeling 
and activation of glucose metabolism and transport (Lopez-Barneo et al., 2001). 
Hypoxia causes regulation of a number of physiologically important genes in 
vasculature, among which are erythropoietin, vascular endothelial growth factor and TH 
(Zhu et al., 2002).  Hypoxic response is studied in various cell lines and it is reported 
that all mammalian cells possess one or more oxygen sensing mechanism or oxygen 
sensor responding to lowered O2. Various cell types within the body are specialized to 
sense changes in pO2, e.g. carotid body and airway neuroepithelial bodies. However, it 
is difficult to proclaim one or more specific O2 sensor (Wenger, 2000). The discovery of 
oxygen regulated transcription factors was a major advancement in the field of O2 
sensing. Hypoxia-inducible factors (HIFs) are well studied for their role in the 
regulation of gene expression for maintaining O2 homeostasis. HIF-1, an O2 regulated 
transcription factor, is ubiquitously expressed and is involved in cellular responses to 
low pO2. HIF-1 plays a vital role as metabolic regulator which allows rapid adaptation 
to oxygen availability. It was initially discovered that HIFs are able to bind to hypoxia 
response elements in the 3´ flanking region of the erythropoietin gene at low 
intracellular oxygen tension. HIF-1 and HIF-2 are heterodimeric transcription factors 
composed of one of two HIF proteins (HIF-1α or HIF-2α) and HIF-1, also known as 
aryl hydrocarbon receptor nuclear translocator (Gardner and Corn, 2008). HIF proteins 
are members of basic helix-loop-helix-Per-Arnt-Sim family of transcription factors. HIF 
proteins have conserved domains which include a basic helix-loop-helix region for 
DNA binding and two per-arnt-sim domains meant for dimerization and target gene 
specificity (Semenza and Wang 1992; Maxwell et al., 1993; Wang and Semenza 1993; 
Semenza, 1999; Wang et al., 1995; Semenza 2000). In normoxic conditions, HIF-1α is 
consistently present in cells whereas HIF-1α is not detectable during normoxia because 
it is rapidly degraded after being synthesized. Hypoxia causes rapid stabilization and 
activation of HIF-1α which is detectable in less than 30 min, and peak response takes 4-
8 hours. Upon normoxia, activity decays very rapidly, having a half life of about 5 min 
(Jiang et al., 1996). Hypoxia increases the HIF-1 activity at multiple levels. It increases 
HIF-1α transcription, mRNA stabilization and nuclear translocation. The most 
important effect of hypoxia on HIF-1α is preventing its degradation. The low levels of 
HIF-1α during normoxia are due to ubiquitination and proteasomal degradation, and 
these are blocked during hypoxia. Exogenous H2O2 can inhibit the increased HIF 
activity by hypoxia while sulfhydryl oxidation reverses hypoxic activation (Ema et al., 
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1999; Huang et al., 1998; Salceda and Caro, 1997). In some pathological states, certain 
gene products also play a role in the ubiquitination and subsequent degradation of HIF-
1α, one such example is the von Hippel-Lindau (VHL) tumor suppressor gene product 
pVHL. In VHL-defective cells, HIF-1α is consistently expressed and stabilized 
(Maxwell et al., 1999; Kroll et al., 1999). It is also observed that hypoxia induced HIF-
1α activity is blocked by rotenone, an inhibitor of mitochondrial complex  (Semenza 
1999; Chandel et al., 1998).  
Activating protein-1 (AP-1) is another transcription factor which is involved in 
various functions; one of them is catecholamine biosynthesis (Shaulian and Karin, 
2001). Growth factors, proinflammatory cytokines, UV radiation and hypoxia can 
activate AP-1, which can regulate various targets (Cummins and Taylor, 2005). It is 
known that hypoxia activates AP-1 in vessels which results in regulation of various 
genes, including TH (Milhorn et al., 1997), vascular endothelial growth factor 
(Salnikow et al., 2002) and endothelial nitric oxide synthase (Hoffmann et al., 2001). 
I.4.1 Hypoxic regulation of TH expression 
The carotid body is an arterial chemoreceptor; it is a small, paired organ of 
neuroectodermal origin. It is located at the carotid bifurcation. During fetal life, 
sympathoadrenal progenitors from the superior cervical ganglia migrate to form this 
organ. It is innervated by afferent sensory nerve fibers from the glossopharyngeal nerve, 
and contains a profuse network of blood vessels. The carotid body is the most 
abundantly perfused organ of the body. It is made of type I cells or glomus cells, which 
are wrapped with processes of glia-like type II cells (Kameda, 2005; Lopez-Barneo, 
2001). The carotid body can rapidly detect any changes in chemical composition of the 
blood. It is well known that the carotid body can be activated by hypoxia, hypercapnia 
and acidosis. Furthermore, it is also activated by low glucose (Peers & Buckler, 1995; 
Pardal and Lopez-Barneo, 2002; Lopez-Barneo, 2001; Garcia-Fernandez et al., 2007; 
Zhang et al., 2007). The type I cells or glomus cells contain secretory vesicles having 
ATP, dopamine, acetylcholine and many others neurotransmitters (Nurse, 2005). The 
dopamine released from secretory vesicles is probably involved in vasodilation in 
response to low pO2. Hypoxic regulation of TH expression has been extensively studied 
in the carotid body. Hypoxia causes up-regulation of TH mRNA expression in the 
carotid body up to 500% after 6 h of hypoxic exposure. This hypoxic response is 
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restricted to type I cells of the carotid body (Millhorn et al., 1993). Hypoxia also 
increases TH enzyme activity in the carotid body (Czyzyk-Krzeska et al., 1992). 
The PC12 cell line is derived from rat adrenal pheochromocytoma (Greene and 
Tischler, 1976). This cell line expresses high levels of catecholamines, especially 
dopamine. It is extensively used to study catecholamine synthesis and release 
mechanism by using different stimulants. An up-regulation of TH mRNA levels and 
increased mRNA stability are also observed in hypoxia exposed PC12 cells (Czyzyk-
Krzeska et al., 1994). An O2 responsive sequence of the TH gene promoter is involved 
in the enhanced TH mRNA expression and its stability (Norris and Millhorn, 1995). 
Additionally, PNMT expression in mouse phechromocytoma cells is upregulated in 
response to hypoxia (Evinger et al., 2000). 
HIFs are also involved in the regulation of TH gene expression in PC12 cells by 
interacting with the hypoxia response elements located in the proximal region of the TH 
promoter (Schnell et al., 2003). TH mRNA transcription is mainly dependent on cAMP 
response element (CRE) activity. In PC12 cells, basal transcription level of TH is 
mediated by transcription factors activity at partial dyad (-17 bp), CRE (-45bp), and AP-
1 (-205 bp) while induced transcription is mainly regulated by CRE activity, while very 
small contributions are from AP-1 and hypoxia response element 1 (-225 bp), and this 
differential regulation is independent of the inducing stimulus (Lewis-Tuffin et al., 
2004).  
I.5 TH regulation by phosphorylation 
Dopamine synthesis is also regulated by phosphorylation of TH at various serine 
(ser) residues such as ser-19, ser-31 and ser-40 sites. TH is phosphorylated at ser-40 
mainly by protein kinase A (PKA) in response to forskolin and cyclic Adenosine mono 
phosphate analogues, and by protein kinase G (PKG) in response to nitric oxide and 
cyclic guanosine monophosphate analogues while protein kinase C (PKC) acts directly 
or indirectly in response to phospholipase C activators (Fig. 2, Dunkley et al., 2004). 
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Fig. 2: The protein kinases and protein phosphatases (PPs) capable of modulating TH 
phosphorylation in vitro and in situ. The protein kinases and PPs able to phosphorylate 
and dephosphorylate TH in vitro at serine residue Ser8, Ser19, Ser31 and Ser40 are 
shown. These four sites are all phosphorylated in situ. There is good evidence that the 
kinases shown in bold and underlined are able to phosphorylate TH in situ but the 
evidence is incomplete for depolarizing stimuli. There is enough evidence that the 
kinases shown in bold but not underlined are able to phosphorylate TH in situ. CaMPK, 
calcium- and calmodulin-stimulated protein kinase; ERK, extracellular signal-regulated 
protein kinase; MAPKAPK, MAPK-activated protein kinase; MSK, mitogen- and 
stress-activated protein kinase; PDPK, proline-directed protein kinase; PKA, protein 
kinase A; PKC, protein kinase C; PKG, protein kinase G; PRAK, p38-
regulated/activated kinase (Dunkley et al., 2004). 
(Adapted from Dunkley et al., 2004, under permission license nr.  2639590089628 from 
John Wiley and sons Inc.) 
 
Calcium and calmodulin-dependent protein kinase II (CaMPKII) is most likely 
responsible for the phosphorylation at ser-19 site in response to depolarizing agents and 
increases intracellular calcium. Extracellular signal-regulated protein kinase (ERK) is 
mainly responsible for the phosphorylation at ser-31 site of TH in response to various 
stimuli. The phosphorylation rate of TH at ser-31 is relatively slower as compared to 
ser-19 and ser-40. The fourth phosphorylation site ser-8 is reported to be less significant 
(Dunkley et al., 2004). 
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1.6 Catecholamine synthesis in arteries 
Little is known about the expression and hypoxic regulation of catecholamine 
synthesis enzymes in the arterial system. Our workgroup previously showed, by using 
radio-immunoassay, dopamine and other catecholamines in control and chemically 
sympathectomized rat aorta and superior mesenteric artery (SMA). Dopamine content 
was unaffected by chemical sympathectomy, whereas levels of norepinephrine and 
epinephrine were significantly reduced in arteries from chemically sympathectomized 
rats (Fig. 3).   
 
 
Fig. 3: Catecholamines content of chemically sympathectomized (6-hydroxydopamine) 
rat aorta and SMA. ,  vs respective control value (n = 6-9). The significance level was 
set as P0.05. DA; Dopamine, NE; Norepinephrine and EP; Epinephrine (Kuncová et 
al., 2007) unpublished data from Dr. Jitka Kuncová, Institute of Physiology, Medical 
Faculty Pilsen, Charles University Prague, Czech Republic) 
 
Functional studies with isolated perfused rat SMA showed an endothelium-
dependent vasodilation in U46619-preconstricted SMAs when pO2 in the superfusion 
medium was lowered from 150 to 125 mmHg. This vasodilation was blocked by the 
specific dopamine D1 receptor antagonist SCH-23990. This vasodilatory response was 
still observed when endothelium was removed, although its magnitude was less as 
compared to the response with endothelium. This suggested a role of locally synthesized 
dopamine in mediating vasodilation in response to lowering pO2 in rat SMA. 
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I.7 Aim of the study 
The main focus of the study was to identify the source of catecholamine 
synthesis in cells of the vascular wall (endothelial and smooth muscle cells) and to 
further elaborate the hypoxic up-regulation of catecholamine synthesizing enzymes 
gene expression in these cells. 
 
The following questions were specifically addressed: 
 
 Do intact arteries express the catecholamine synthesizing enzymes? 
 Do isolated and cultured vascular cells express the catecholamine synthesizing 
enzymes? 
 What is the influence of hypoxia on this enzymatic machinery in isolated and 
cultured vascular cells? 
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II Material and Methods 
II.1 Cell culture  
To isolate endothelial cells, adult female wistar rats weighing 240-260 g (for 
lung microvascular endothelial cells n=7, and for aortic endothelial cells n=6) were 
used. The rats were obtained from the animal facility of the Institute for Physiology, 
Justus-Liebig-University Giessen. 
II.1 Lung microvascular endothelial cell culture  
Day 1: Preparation of anti-RECA antibody coupled dynabeads® 
In order to couple anti-RECA antibody to dynabeads® (Dynal A.S., Oslo, Norway), 25 
l of dynabeads® were taken in a 1.5 ml test tube and the test tube was placed in a 
magnetic particle concentrator (Dynal MPC®-E, Dynal A.S., Oslo, Norway) for ~3 min. 
The dynabeads® attached to the wall of the test tube facing the magnet and then the 
supernatant was removed. Then, 1 ml of wash buffer (phosphate buffered saline PBS 
pH 7.4 and 0.1 % bovine serum albumin BSA, filter sterilized) was added and gently 
mixed with the dynabeads®. The test tube was placed again in the magnetic particle 
concentrator for ~3 min and the supernatant was removed. This wash process was 
repeated 3 times.  
Then, mouse anti-RECA antibody (Clone HIS52, Serotec, U.K.) was diluted 
1:100 in wash buffer I, mixed gently with the dynabeads® and this mixture was placed 
overnight at 2-8C. 
Day 2: Isolation of rat lung endothelial cells  
The beads were again washed 2 times with wash buffer I. The rats were sacrificed by 
inhalation of isoflurane (Baxter, Unterschleißheim, Germany). The thorax was opened 
and 0.2 ml of heparin (5000 IU/ml, Ratiopharm, Ulm, Germany) was injected into the 
left ventricle of the heart. To perfuse the pulmonary vasculature, a small opening was 
made into the right ventricle and a cannula was inserted. An opening was also made into 
the left atrium as an outlet of perfusion. The animal was perfused with rinsing solution 
consisting of polyvinylpyrrolidone 12.5 g, NaCl 4.5 g and procainhydrochloride 2.5 g 
dissolved in 500 ml water, to which 500 l of heparin was added prior to use. This 
rinsing solution was followed by ice-cold DMEM medium (PAA Laboratories GmbH, 
Marburg, Germany) with 1% penicillin/streptomycin (P/S; PAA Laboratories GmbH, 
Marburg, Germany). 
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After perfusion, the lung was removed and placed in a petri dish with 15 ml of DMEM 
medium with 10% P/S. In a laminar flow cabinet, the lung was cut into small pieces 
with a small scissor. These pieces were placed in collagenase solution (0.5% 
collagenase, 0.5% bovine serum albumin and 10% P/S in DMEM, sterile filtered) with 
continuous agitation at room temperature for 45 min. The mixture was filtered through a 
20-30 m pore size filter. The filtrate was collected in a 50 ml sterile tube (Greiner Bio-
One GmbH, Frickenhausen, Germany) and centrifuged at 377xg for 5 min. The 
supernatant was removed and the pellet was resuspended in 10 ml of DMEM medium 
with 10% P/S and centrifuged at 377xg for 5 min. This process was repeated again and 
the cell pellet was resuspended in a 1 ml volume of DMEM medium with 10% P/S and 
transferred to 2 ml sterile test tube. Anti-RECA antibody coupled dynabeads® were 
added to this test tube and incubated at 2-8C for 30 min. The test tube was placed in 
the magnetic particle concentrator for ~4 min, the supernatant was removed and the 
endothelial cell-anti-RECA antibody-dynabeads® complexes were washed with DMEM 
medium with 10% P/S. This wash process was repeated 2 times. After washing, the 
endothelial cell-anti-RECA antibody-dynabeads® complexes were transferred to a 75 
cm2 cell culture flask (NUNC, New York, USA) with 10 ml of endothelial cell growth 
medium MV (Promo cell, Heidelberg, Germany). The medium was replaced every 2nd 
day and the cells were trypsinized when confluent. Cells were trypsinized according to 
the process described in II.3.  
II.2 Aortic endothelial cell culture 
Day 1 
The day 1 procedure for coupling of anti-RECA antibody to dynabeads® was the same 
as for isolation of lung endothelial cells (II.1) 
Day 2  
The rats were sacrificed by inhalation of isoflurane (Baxter, Unterschleißheim, 
Germany). The thorax was opened and 0.2 ml of heparin (5000 IU/ml, Ratiopharm, 
Ulm, Germany) was injected into the left ventricle of the heart. In order to perfuse the 
systemic vasculature, a small opening was made into the left ventricle and a cannula 
was inserted. An opening was also made into the right atrium as an outlet of perfusion. 
The animal was perfused with rinsing solution, followed by ice-cold DMEM medium 
with 1% P/S. 
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After perfusion, the aorta was removed and placed in a petri dish with 15 ml of 
DMEM medium with 10% P/S. In a laminar flow cabinet, the aorta was cut into small 
pieces with a small scissor. These pieces were placed in collagenase solution (0.5% 
collagenase, 0.5% bovine serum albumin and 10% P/S in DMEM, sterile filtered) with 
continuous agitation at room temperature for 45 min. The mixture was filtered through a 
20-30 m pore size filter. The filtrate was collected in a 50 ml sterile tube (Greiner Bio-
One GmbH, Frickenhausen, Germany) and centrifuged at 377xg for 5 min. The 
supernatant was removed and the pellet was resuspended in 10 ml of DMEM medium 
with 10% P/S and centrifuged at 377xg for 5 min. This process was repeated again and 
the cell pellet was resuspended in a 1 ml volume of DMEM medium with 10% P/S and 
transferred to 2 ml sterile test tube. Anti-RECA antibody coupled dynabeads® were 
added to this test tube and incubated at 2-8C for 30 min. The test tube was placed in 
the magnetic particle concentrator for ~4 min, the supernatant was removed and the 
endothelial cell-anti-RECA antibody-dynabeads® complexes were washed with DMEM 
medium with 10% P/S. This wash process was repeated 2 times and then the endothelial 
cell-anti-RECA antibody-dynabeads® complexes were transferred to a 75 cm2 cell 
culture flask (NUNC, New York, USA) with 10 ml of endothelial cell growth medium 
MV (Promo cell, Heidelberg, Germany). The medium was replaced every 2nd day and 
the cells were trypsinized when confluent.  
II.3 Trypsinisation of cells 
Cells were trypsinized at 90% confluency. The medium was removed, the cells 
were washed with a small amount (3 ml) of trypsin solution (PAA Laboratories GmbH, 
Marburg, Germany) and then 5 ml of trypsin solution was added and the flask was 
placed at 37C in an incubator until all the cells were detached (~5 min). Then, 5 ml of 
prewarmed endothelial cell growth medium was added to the flask. The contents were 
mixed with a 10 ml plastic pipette and transferred to a 15 ml sterile centrifuge tube and 
centrifuged at 377xg for 5 min. The supernatant was removed and the cell pellet was 
resuspended in 3 ml of prewarmed endothelial cell growth medium. 
Cells from one 75 cm2 flask were usually splitted to 4 flasks (each 75 cm2) for 
expansion. 
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II.4 Characterization of endothelial cells 
EC were characterized by 1,1’-dioctadecyl-3,3,3’,3’-tetramethyl-
indocarbocyanine perchlorate labeled acetylated low density lipoprotein (DiI-Ac-LDL; 
Paesel & Lorei, Hanau, Germany) uptake and by immunolabelling for von Willebrand 
factor (vWF).  
II.4.1 DiI-Ac-LDL uptake 
EC were cultured in 8-well cell culture slide (NUNC, New York, USA) for 48 
hours. EC were incubated with DiI-Ac-LDL, 10 g/ml at 37C for 4 hours. Then, the 
EC were washed with pre-warmed cell growth medium followed by 5 min wash with 
PBS, were fixed using 4% PFA for 10 min and washed with PBS 2 x 10 min. For 
nuclear labeling, the EC were incubated with 4’,6-diamidino-2-phenylindole 
dihydrochloride (DAPI; 1 mg/ml Sigma, St. Louis, USA 1:5000 diluted in PBS) for 10 
min, followed by washing with PBS 2 x 10 min. The slides were covered with Mowiol 
4-88 (Calbiochem, Darmstadt, Germany) and stored at 4C until microscopy. 
II.4.2 Immunolabelling for vWF 
EC were cultured in 8-well sterile culture slides (NUNC, New York, USA). At 
80-90 % confluency, cells were washed with PBS for 5 min and fixed with ice cold 
methanol (Merck, Darmstadt, Germany) for 15 min, followed by incubation with 
blocking solution (5% BSA and 5% normal goat serum in PBS) for 1 h at room 
temperature. 
The EC were incubated overnight at room temperature with rabbit-anti-human 
vWF antibody (cat # A0082, Dako Cytomation, Glostrup, Denmark), diluted 1:300 in 
PBS with 0.05 M NaCl and 0.01% NaN3 (PBS+NaCl+NaN3). After overnight 
incubation with primary antibody, the EC were washed with PBS 2 x 10 min and 
incubated with secondary antibody (FITC-conjugated goat-anti rabbit IgG; Cappel, 
Aurora, USA) diluted 1:400 in PBS+NaCl+NaN3, for 1 h at room temperature. The EC 
were again washed with PBS 2 x 10 min. For nuclear labeling, the EC were incubated 
with DAPI (1 mg/ml; 1:5000 diluted in PBS) for 10 min, followed by washing with 
PBS 2 x 10 min. The EC were post-fixed with 4% paraformaldehyde (PFA) for 10 min, 
washed 2 x 10 min with PBS and cover-slipped with mowiol 4-88. Slides were kept at 
4C until microscopy. 
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II.5 Isolation of aortic smooth muscle cells 
The rats were sacrificed by inhalation of isoflurane (Baxter, Unterschleißheim, 
Germany). The thorax and the abdomen were opened and 2 ml of heparin (5000 IU/ml, 
Ratiopharm, Ulm, Germany) was injected into the left ventricle of the heart. In order to 
perfuse the systemic vasculature, a small opening was made into the left ventricle and a 
cannula was inserted. An opening was also made into the right atrium as an outlet of 
perfusion. The animal was perfused with rinsing solution, followed by ice-cold DMEM 
medium with 1% P/S. 
The aorta was removed and placed in ice-cold DMEM medium. With the help of 
a dissecting microscope the surrounding tissues were removed and the aorta was cut 
into two parts: thoracic and abdominal aorta. 
The aorta was cut open longitudinally and the endothelium was removed with 
the help of a cotton swab. Then, the opened aorta was cut into small pieces (1-2 mm) 
and placed in a sterilized 24-well plate (Greiner Bio-One GmbH, Frickenhausen, 
Germany). Smooth muscle growth medium (Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 [DMEM/F12; Invitrogen GmbH, Karlsruhe, Germany] 20% fetal 
calf serum [FCS; Hyclone Fisher Scientific, Schwerte, Germany], 1% P/S) was added to 
the wells containing aortic pieces. The medium was changed every 2nd day. After 4-6 
days, smooth muscle cells start to migrate out of the graft. The cells were transferred to 
a 75 cm2 flask for expansion. Later the cells were trypsinized according to II.3. 
II.5.1 Characterization of smooth muscle cells 
Aortic smooth muscle cells were characterized by immunolabelling of α-smooth 
muscle actin with FITC-conjugated mouse monoclonal anti-smooth muscle actin 
antibody (Clone 1A4; Sigma, St. Louis, USA) 
II.5.2 Procedure for immunolabelling 
For immunolabelling, the cells were cultured in 8-well culture slides (NUNC, 
New York, USA). The 80-90% confluent cells were used for immunolabelling with 
anti-smooth muscle actin antibody. The cells were washed with PBS and then fixed with 
4% PFA for 15 min, followed by washing for 5 min with PBS. The cells were treated 
with 0.1% triton x-100 (Merck, Darmstadt, Germany) for 10 min to make the cell 
membrane permeable, and washed with PBS for 5 min. The cells were incubated with 
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blocking solution (5% BSA and 5% NGS in PBS) for 1 h at room temperature. The cells 
were incubated overnight at room temperature with FITC-conjugated anti-smooth 
muscle actin antibody from mouse, diluted 1:500 in PBS+NaCl+NaN3. After overnight 
incubation, the cells were washed with PBS 2 x 10 min. 
For nuclear labeling, the smooth muscle cells were incubated with DAPI (stock 
solution 1 mg/ml) 1:5000 diluted in PBS for 10 min, followed by washing with PBS 2 x 
10 min. Then cells were again fixed with 4% PFA for 10 min, washed with PBS 2 x 10 
min and coverslipped with mowiol 4-88. Slides were kept at 4C until microscopy. 
II.6 Exposure of vascular cells to hypoxia 
Vascular cells (endothelial and smooth muscle cells) were exposed to hypoxia 
(1% O2, 5% CO2, and 94% N2) in an incubator at 37C. For hypoxic exposure, the cells 
were cultured in 6-well plates (for total RNA isolation) and in 75 cm2 culture flasks (for 
protein extraction). The cells were exposed to hypoxia for 6, 12 and 24 h in an incubator 
at 37C. At the same time, a normoxic (20% O2, 5% CO2) control was also included in 
each experiment. After hypoxic and normoxic exposure the samples were processed for 
PCR and western blotting as follows. 
II.7 Polymerase chain reaction (RT-PCR) 
II.7.1 RNA isolation 
For total RNA isolation, Rneasy Mini Kit (Qiagen, Hilden, Germany) was used 
according to the instruction manual provided in the kit. After total RNA isolation, the 
RNA quantity was measured with a Bio photometer (Eppendorf, Hamburg, Germany) 
and the total RNA was stored at -80C until further work. 
II.7.2 cDNA Synthesis 
For cDNA synthesis, 1 μg of total RNA was first exposed to DNase (Invitrogen 
GmbH, Karlsruhe, Germany) to remove any left-over traces of DNA during RNA 
isolation. For this purpose, 1 μg of total RNA was mixed with 1 μl DNase-I (1 U/μl, 
Invitrogen GmbH) and 1 μl 10x DNase I Reaction Buffer (Invitrogen GmbH, 
Karlsruhe), and incubated for 15 min at 25°C. The DNase reaction was stopped by 
adding 1 μl of EDTA (25 mM, pH 8.0; Invitrogen GmbH) and heating the mixture to 
65°C for 10 min.  
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After this step, the mixture was immediately cooled to 4°C by placing on ice. 
For reverse transcription, 1 μl of oligo dTs (MWG Biotech AG, 
Ebersberg, Germany), and 1 μl of dNTPs (10 mM of each dNTP; Qiagen, Hilden, 
Germany), 2 μl dithiolthreitol (0.1 M; Invitrogen GmbH), 1 μl Superscript II Revese 
Transcriptase (200 U/μl, Invitrogen GmbH) and 4 μl 5x First Strand Buffer (Invitrogen 
GmbH) were incubated at  42°C for 2 min followed by incubation at 42°C for 50 min. 
At the end of cDNA synthesis reaction, the mixture was heated to 72°C for 10 min for 
inactivation of Superscript II. The cDNA was stored at -20°C. 
II.7.3 Real-time reverse transcription-polymerase chain reaction  
Real-time reverse transcription-polymerase chain reaction (real-time RT-PCR) 
was performed with an I-Cycler (Bio-Rad, Munich, Germany) by using iQTM SYBR® 
Green Supermix (Bio-Rad, Munich, Germany). This master mix contains all the 
necessary ingredients required for qPCR. For setting up the reaction, 2 l of 1:2 diluted 
cDNA was added to 12.5 l of iQTM SYBR® Green Supermix and 0.5 l (20 pM) of 
intron spanning forward and reverse primer pairs (table 1) and 10 l of H2O . 
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Primer Sequence Product 
length 
(DNA 
fragment 
position) 
Accession 
number 
 
TH 
 
Forward ACGTCCCCAAGGTTCATC 
Reverse TACAGCCCGAGACAAGGA 
 
216 bp 
(99-314) 
 
NM_012740 
 
 
DDC 
 
Forward AGAGGGAAGGAGATGGTGGA 
Reverse GTGGGGAAGTAAGCGAAGAAGT 
 
221 bp 
(302-122) 
 
NM_008890 
 
 
DH 
 
Forward AGCCCCTTCCCTTACCACA 
Reverse TGCGTTCTCCATCTCACCTC 
 
162 bp 
(148-309) 
 
NM_031144 
 
 
PNMT 
 
Forward GCGAGGGTGAAGCGAGTC 
Reverse GGCAGAAGGCAGAGACCAAG 
 
106 bp 
(495-564) 
 
NM_012512 
 
 
2MG 
 
Forward TGTCTCAGTTCCACCCACCT 
Reverse GGGCTCCTTCAGAGTGAC 
 
252 bp 
(49-262) 
 
NM_031144 
 
 
-actin 
 
Forward CAACCTTCTTGCAGCTCCTC 
Reverse AGGGTCAGGATGCCTCTCTT 
 
191 bp 
(147-338) 
 
NM_012512 
 
Table 1: Rat primer pairs used for real-time RT-PCR (TH: tyrosine hydroxylase; DDC: 
dopa decarboxylase; DH: dopamine--hydroxylase; PNMT: phenylethanolamine-N-
methyltransferase; 2MG: -2-microglobulin) 
 
The conditions for real-time RT-PCR were as follows: The mixture was 
incubated for 10 min at 95C for activation of DNA polymerase, followed by 45 cycles 
(20 s at 95C, 20 s at 60C and 20 s at 72C) for the extension. At the end of the PCR 
cycles, melting curves of the products were analyzed. All the samples were run in 
triplicate and the mean cycle threshold (CT) values were taken for further analysis. 
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Primer Sequence Product 
length 
(DNA 
fragment 
position) 
Accession 
number 
 
TH 
 
Forward ACCCTGACCTGGACTTGG 
Reverse CAATCTCCTCGGCGGTGT 
 
138 bp 
(663-800) 
 
NM_199292 
 
 
DDC 
 
Forward AGAGGGAAGGAGATGGTGGA 
Reverse AGTGGGGAAGTAGGCGAAGA 
 
222 bp 
(226-442) 
 
NM_001082971 
 
 
DH 
 
Forward CTCTCGGCACCACATTATCA 
Reverse TCGGGTTTCATCTTGGAGTC 
 
147 bp 
(732-878) 
 
NM_000787 
 
 
PNMT 
 
Forward GCAGCCACTTTGAGGACATC 
Reverse CAAGCAGAAGGCAGAGACCA 
 
281 bp 
(494-774) 
 
NM_002686 
 
 
2MG 
 
Forward TTCACCCCCACTGAAAAAGA 
Reverse AGCAAGCAAGCAGAATTTGG 
 
160 bp 
(328-487) 
 
NM_004048 
 
Table 2: Human primer pairs used for real-time RT-PCR (TH: tyrosine hydroxylase; 
DDC: dopa decarboxylase; DH: dopamine--hydroxylase; PNMT: 
phenylethanolamine-N-methyltransferase; 2MG: -2- microglobulin) 
II.7.4 Gel electrophoresis 
The PCR product size was analyzed by gel electrophoresis in 2% agarose gel 
(Genegarose L.E.; iNNO-TRAIN Diagnostik GmbH, Kronberg, Germany) in Tris-
acetate-EDTA buffer (482 g/l TRIS [USB, Cleveland, USA], 104.2 ml/l glacial acetic 
acid [Merck, Darmstadt, Germany], 200 ml/l 0.5 M EDTA [Invitrogen, Karlsruhe, 
Germany] up to 1 l with distilled H2O, pH 8.0). Ethidium bromide 1 l (1%; Roth 
GmbH, Karlsruhe, Germany) was added to label the PCR product for visualization with 
an UV transilluminator (Biometra, Göttingen, Germany) 
II.7.5 Data analysis 
The real-time RT-PCR data was analyzed by comparative method or ∆∆CT 
method of relative quantification. In this method amounts of target are calculated by 
using CT values as described below. 
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First of all, the ∆CT value for each sample is determined by calculating the 
difference between the CT value of the target gene and the CT value of the house 
keeping gene. In this study -2 microglobulin (2MG) was used as house keeping gene.  
 ∆CT (sample) = CT target gene – CT 2MG 
To compare normoxic with hypoxic samples, ∆∆CT was calculated by the following 
formula: 
∆∆CT = ∆CT (sample) - ∆CT (control) 
Control is normoxic and sample is hypoxia exposed. 
From this ∆∆CT value, relative expression was calculated by following the 
formula 2-∆∆CT. This gives the gene expression relative to normoxic conditions. 
The data were analyzed for significance by Kruskal-Wallis test and Mann-Whitney-U 
test, and data are presented as box plots by using the software program SPSS Version 
15.0 (SPSS GmbH Software, Munich, Germany). Probability (P) values of less than 
0.05 were considered significant (P<0.05). 
II.8 Western blot  
II.8.1 Protein extraction 
Protein extract from tissue/cells was made by urea extraction buffer (8 M urea 
[Merck], 10 % glycerol [Merck], 5% SDS  [Merck], 1 M Tris pH 6.8  [Merck], 1 M 
DTT [dithiotheritol, Sigma], 100 mM PMSF [phenylmethylsulphonyl fluoride, Sigma]) 
and one tablet of complete protease inhibitor cocktail (Roche Diagnostics GmbH, 
Mannheim, Germany) per 10 ml of buffer. 
Tissue/cells were extracted in a five fold excess (v/w) of extraction buffer. The 
tissue/cells were homogenized by a ball mill homogenizer (Retsch, Haan, Germany) for 
5 min at maximum speed (30 strokes/s). Later, the extract was centrifuged for 2-3 min 
at 6800xg to get a clear extract.  
II.8.2 Protein gel electrophoresis 
Protein electrophoresis was done by SDS-PAGE. The seperating gel containing 
10% acrylamide was made by 10 ml of 30% acrylamid (Roth, Karlsruhe, Germany), 5.6 
ml 2 M TRIS-HCl, pH 8.8, 150 μl 20% SDS (Serva, Heidelberg, Germany), 160 μl 10% 
ammoniumpersulfate (APS; Merck, Darmstadt, Germany), 12 μl TEMED (TEMED; 
Tetramethylethylenediamine, Roth, Karlsruhe, Germany) and 9.25 ml H2O. The 
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stacking gel consisted of 1 ml 30% acrylamide, 50 μl 20% SDS, 1.25 ml 1 M TRIS-
HCl, pH 6.8, 80 μl 10% APS, 10 μl TEMED and 7.7 ml H2O. 
Before loading, the protein extracts were mixed with 5x concentrated sample 
buffer (320 mM Tris-HCl, pH 6.8, 5% SDS, 50% glycerol, and 0.25 mg/ml 
bromphenolblue and 1% β-2-mercaptoethanol) and heated to 95°C for 5 min. Protein 
extracts were applied 5-10 l per lane. For reference, 10 l of prestained protein marker 
(Biorad, Munich, Germany) was also applied in one lane as reference of molecular 
weight of protein. The running buffer consisted of 0.025 M TRIS, 0.192 M glycine and 
2.5 ml 20% SDS in one litre water. The stacking gel was electrophoresed for 15-20 min 
at 100 V (Power supply from Hoefer Scientific Instruments, San Francisco, USA) for 
separation of proteins; the separation gel was electrophoresed at 200 V for 40-50 min. 
After electrophoresis, the proteins were transfered from the gel to a polyvinylidene 
fluoride (PVDF) membrane (Millipore, Schwalbach, Germany) in semi-dry conditions 
(Semi-dry electroblotter; Sartorius, Goettingen, Germany). Before transfer, the PVDF 
membrane was activated according to the manufacturer’s protocol. For transfer, filter 
paper, PVDF membrane and the gel were soaked in a blotting buffer (NuPAGE Transfer 
Buffer, Invitrogen, Karlsruhe, Germany). The transfer was done for 90 min at 6 V. 
After transfer, the PVDF membrane was incubated for 1 h at room temperature 
in blocking buffer consisting of 10% milk powder (Roth, Karlsruhe, Germany) in 
tween-tris-buffered saline (TTBS; 0.01 M Tris-HCl [pH 8.0], 0.2 NaCl and 0.05% 
Tween-20). 
After blocking, the membrane was incubated with primary antibody (mouse 
anti-tyrosine hydroxylase antibody; ms-α-TH, clone 2/40/50; Chemicon international, 
Temecula, USA) diluted 1:2,000 in 5% milk powder TTBS overnight at room 
temperature. After overnight incubation, the membrane was washed with TTBS 6x5 
min and incubated with peroxidase-conjugated secondary antibody (goat anti-mouse-
IgG, 1:10,000 dilution; Pierce, Bonn, Germany) in 2.5% milk powder TTBS for 1 h at 
room temperature. Membranes were washed again with TTBS 6x5 min. For visualizing 
the protein, chemiluminescence substrate (Super Signal West Pico Chemiluminescence 
Substrate, Pierce, Bonn, Germany) was applied to the membranes for 5 min according 
to the instructions of manufacturer. For the visualization of the chemiluminescence 
reaction, the membranes were exposed to x-ray films (Amersham, Munich, Germany) 
for various periods of time.  
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II.9 Dissection of rat vessels for real-time RT-PCR and western blotting 
To isolate various vessels, adult female wistar rats weighing 240-260 g (for real-
time RT-PCR n=5, and for western blotting n=4) were used. The rats were obtained 
from the animal facility of the Institute for Physiology, Justus-Liebig-University 
Giessen. 
The rats were sacrificed by inhalation of isoflurane (Baxter). The thorax was 
opened and 0.2 ml of heparin (5,000 IU/ml, Ratiopharm) was injected into the left 
ventricle of the heart. Rat thoracic aorta, abdominal aorta, superior mesenteric and 
femoral were removed, given a quick wash in ice-cold saline, and frozen at -80C. 
Later, these samples were processed for real-time RT-PCR (III) and western blot (IV). 
II.10 Primary human vascular cell culture 
Primary human vascular cells were obtained from Lonza (Verviers, Belgium). 
Human microvascular endothelial cells of the lung (HMVEC-L; cat # CC-2527), human 
aortic endothelial cells (HAEC; cat # CC-2535) and human pulmonary artery 
endothelial cells (HPAEC; cat # CC-2530) were cultured in the endothelial cell basal 
medium (cat# CC-3121, Lonza) supplemented with the various growth factors (cat # 
CC-4147; Lonza) according to the instructions from the supplier and were characterized 
according to protocols (II.4).  
 Human aortic smooth muscle cells (HAOSMC; cat # CC-2571) were cultured in 
the smooth muscle cell growth medium (Lonza) according to the instructions from the 
supplier and were characterized according to protocols (II.5.1). 
II.11 Exposure of primary human vascular cells to hypoxia 
Primary human vascular cells were exposed to hypoxia according to protocol 
(II.6). 
II.12 Western blotting and real-time RT-PCR 
Western blotting from primary human vascular cells exposed to normoxia and 
hypoxia was done according to protocol (II.7), and qPCR was done according to (II.8) 
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II.13 Immunohistochemistry  
II.13.1 Dissection, fixation and processing of vessels 
Adult female wistar rats weighing 240-260 g (n= 3) were used. The rats were 
obtained from the animal facility of the Institute for Physiology, Justus-Liebig-
University Giessen. 
The rats were sacrificed by inhalation of isoflurane (Baxter). The thorax was 
opened and 0.2 ml of heparin (5,000 IU/ml, Ratiopharm) was injected into the left 
ventricle of the heart. Rat thoracic aorta, abdominal aorta, superior mesenteric and 
femoral was removed, given a quick wash in ice cold saline and placed immediately in 
4% paraformaldehyde (PFA; Roth, Karlsruhe, Germany) in 0.1 M phosphate buffer, pH 
7.4, for fixation for 4 h. Later, the tissues were washed overnight in 0.1 M phosphate 
buffer, pH 7.4. 
After overnight wash, the vessels were placed overnight in 18% sucrose (Roth, 
Karlsruhe, Germany) in 0.1 M phosphate buffer. The next day, fixed tissues were 
shock-frozen in liquid nitrogen and stored at -20 C. 
The frozen PFA-fixed tissues were cut with a cryostat to 10 m thick sections. 
The sections were fixed with histo block solution (10% horse serum, 0.5% tween and 
0.1 % BSA in PBS, pH 7.4) for 1 hour at room temperature. 
Then, the sections were incubated overnight at room temperature with rabbit 
anti-tyrosine hydroxylase antibody (Biotrend) diluted 1:400 in PBS+NaCl+NaN3. The 
sections were washed with PBS 2x10 min and incubated with Cy3-conjugated donkey 
anti-mouse-IgG antibody (Dianova, Hamburg, Germany) diluted 1:1000 in 
PBS+NaCl+NaN3 for 1 h at room temperature. After incubation with secondary 
antibody, the sections were again washed with PBS 2x10 min and post-fixed with 4% 
PFA for 10 min. 
The sections were washed again 2x10 min with PBS, coverslipped with mowiol-
488 and stored at 4C. 
II.13.2 Preabsorption test 
The specificity of the primary antibody labelling was tested by incubating the 
primary antibody (rabbit anti-tyrosine hydroxylase antibody) with the antigen (tyrosine 
hydroxylase, 1 g/l; Biotrend, Cologne, Germany) for 1 h at room temperature. This 
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mixture was used in immunohistochemistry. As positive control, primary antibody 
without antigen was used.  
II.13.3 Microscopy/Epifluorescence microscopy 
 The slides with fluorescence labeled tissue sections were analyzed by an 
epifluorescence microscope (Axioplan 2 Imaging, Zeiss, Jena, Germany) fitted with a 
camera (Axio Cam, Zeiss). The images were captured by the camera with the help of 
Axiovision 4 and 4.7 software (Zeiss).  
The filters with specific wavelength for excitation and absorption spectra for various 
fluorochromes/fluorophores are listed in table 3. 
 
Fluorochrome Excitation filter 
(nm) 
Barrier filter 
(nm) 
Cyanine 3 (Cy3) 525-560 570-650 
DAPI 360-370 420-460 
Fluorescein isothiocyanate 
(FITC) 
460-490 515-550 
 
Table 3: The filters used for immunohistochemistry.  
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III Results 
III.1 Cell culture 
III.1.1 Endothelial cell culture from rat 
Rat lung microvascular and aortic EC were isolated, expanded and characterized 
by uptake of DiI-Ac-LDL (Fig. 4 A, B) and by immunoreactivity to vWF. 
Immunolabeled cells showed dot-like structures within the cytoplasm (Fig. 4 C, D). The 
labeling was absent when the cells were incubated without primary antibody (Fig. 4 E). 
 
Fig. 4: The purity of isolated EC was controlled by use of specific EC markers. (A) Rat 
lung microvascular EC and (B) aortic EC show uptake of DiI-Ac-LDL. (C) Rat lung 
EC, (D) rat aortic EC were immunolabeled with anti-vWF antibody. (E) The negative 
control, lung EC incubated with secondary antibody only, showed absence of labeling. 
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III.1.2 Endothelial cell culture from human 
Primary human EC (lung microvascular, aortic and pulmonary artery) were 
purchased from Lonza, cultured and characterized by uptake of DiI-Ac-LDL (Fig. 5 A, 
B, C).  
 
Fig. 5: The purity of EC was controlled by use of specific EC markers. (A) Human lung 
microvascular EC, (B) human aortic EC and (C) human pulmonary artery EC, showed 
uptake of DiI-Ac-LDL. 
 
The cells were further characterized by immunoreactivity to vWF. 
Immunolabeled cells showed dot-like structures within the cytoplasm (Fig. 6 A, B, C). 
The labeling was absent when the cells were incubated without primary antibody (Fig. 6 
D). 
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Fig. 6: The purity of EC was controlled by use of specific EC markers. (A) Human lung 
microvascular EC, (B) human aortic EC and (C) human pulmonary artery EC were 
immunolabeled with anti-vWF antibody. (D) The negative control, human lung EC 
incubated only with secondary antibody showed absence of labeling. 
III.1.3 Smooth muscle cell culture from rat 
Smooth muscle cells were isolated and cultured from rat thoracic and abdominal 
aorta. These cells were characterized by immunolabelling of -smooth muscle actin 
(sm-actin) in smooth muscle cells (Fig. 7 A, B). 
 
Fig. 7: Smooth muscle cells were immunolabeled with FITC-conjugated mouse 
monoclonal -smooth muscle actin-antibody. (A) Rat thoracic aortic and (B) rat 
abdominal aortic smooth muscle cells were immunolabeled. 
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III.1.4 Smooth muscle cell culture from human 
Human aortic smooth muscle cells were purchased from Lonza, cultured and 
characterized by immunoreactivity to -smooth muscle actin in smooth muscle cells 
(Fig. 8). 
 
Fig. 8: Human aortic smooth muscle cells were immunolabeled with FITC-conjugated 
mouse monoclonal -smooth muscle actin-antibody. 
III.2 Immunohistochemistry of rat arteries 
III.2.1 Thoracic and abdominal aorta  
TH, the rate limiting enzymatic step of catecholamine biosynthesis, was detected 
by immunohistochemistry in sections of rat thoracic and abdominal aorta. The EC and 
the smooth muscle cells of the both parts of aorta were immunolabeled. No nerve fiber 
labeling was observed in both cases (Fig. 9 A, C). This labeling was not detectable 
when the TH-antibody has been preabsorbed with its cognate antigen (Fig. 9 B, D) and 
when the primary antibody was omitted (Fig. 9 E). 
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Fig. 9: TH-Immunolabelling, rat aorta. Rat thoracic (A) and abdominal aorta (C) are 
labeled with rabbit polyclonal anti TH-antibody. (B, D) Immunolabelling was absent 
after preabsorption of the antibody with corresponding peptide. (E) No immunolabelling 
was detectable in negative control, when sections were incubated without primary 
antibody. L: Lumen; EC: Endothelial cells; SMC: smooth muscle cells and Ad: 
adventitia. 
III.2.2 Femoral artery 
TH was detected in sections of rat femoral artery by immunohistochemistry. The 
EC and the smooth muscle cells of the artery were immunolabeled as well as 
sympathetic nerve fibers (Fig. 10 A). This labeling was not detectable when the TH-
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antibody has been preabsorbed with its cognate antigen (Fig. 10B). This labeling was 
also not detectable when the primary antibody was omitted (Fig. 10 C). 
 
 
Fig. 10: TH-Immunolabelling, rat femoral artery. Rat femoral artery (A) was 
immunolabeled with rabbit polyclonal anti TH-antibody. (B) Immunolabelling was 
absent after preabsorption of the antibody with corresponding peptide (C) No 
immunolabelling was detectable in negative control, when sections were incubated 
without primary antibody. L: Lumen; EC: Endothelial cells; SMC: smooth muscle cells 
and “     ” is for nerve fibers. 
III.2.3 Superior mesenteric artery 
TH was detected in sections of rat superior mesenteric artery by 
immunohistochemistry. The EC and the smooth muscle cells of the artery were 
immunolabeled as well as sympathetic nerve fibers (Fig. 11 A). In EC and smooth 
muscle cells, this labeling was not detectable when the TH-antibody has been 
preabsorbed with its cognate antigen (Fig. 11 B). The labeling was not detectable when 
the primary antibody was omitted (Fig. 11 C). 
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Fig. 11: TH-immunolabeling in rat superior mesenteric artery. (A) Rat superior 
mesenteric artery was immunolabeled with rabbit polyclonal anti TH-antibody. (B) 
Immunolabelling was absent after preabsorption of the antibody with corresponding 
peptide, nerve fibers were still labeled. (C) No immunolabelling was detectable in 
negative control, when sections were incubated without primary antibody. L: Lumen; 
EC: Endothelial cells; SMC: smooth muscle cells and “        ” is for nerve fibers. 
III.2 Western blot 
III.2.1 Rat arteries 
TH, the rate limiting enzyme in catecholamine synthesis, was also detected by 
western blot of the protein extracts from rat vessels (thoracic and abdominal aorta and 
femoral artery). A TH-immunoreactive band was detected at 56 kDa by a mouse 
monoclonal anti-TH antibody (Fig. 12). Adrenal gland protein extract was used as the 
positive control and a negative control was run without primary antibody. Other visible 
bands were might be phosphorylated forms of TH.  
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Fig. 12: Western blot analysis of the protein extracts from rat thoracic and abdominal 
aorta and femoral artery, while rat adrenal gland protein extract was used as positive 
control. TH was detected by western blot in all arteries with the expected molecular 
weight of 56 kDa, marked with red arrow. The strongest signal was observed in adrenal 
gland extract. A negative control was run without primary antibody from protein extract 
of each sample.  
III.2.2 Rat lung EC 
 Rat lung EC were exposed to hypoxia (1% O2) for 6, 12 and 24 hours, and a 
normoxic control was also included in this setup. The protein extracts from these EC 
were analyzed by western blotting for the expression of TH. Hypoxia causes an up-
regulation of TH expression in rat lung EC (Fig. 13). 
 
 
Fig. 13: Expression of TH in rat lung EC exposed to hypoxia and normoxia. A 56 kDa 
band was detected which corresponds to the expected size of the TH protein. There was 
up-regulation of TH protein expression with increasing hypoxic exposure.  
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III.3 Real-time RT-PCR 
III.3.1 PCR Efficiency curves 
 PCR efficiency curves were made by serial dilution of rat adrenal gland cDNA, 
as this organ expresses high amount of catecholamine synthesizing enzymes. The PCR 
efficiencies calculated were 89.2% for TH (Fig. 14 A), 102.6% for DDC (Fig. 15 A), 
104.5% for DH (Fig. 16 A) and 95.2% for PNMT (Fig. 17 A). The cDNA from rat 
adrenal gland was serially diluted (e.g. 1:10, 1:100, 1:1000 and 1:10,000). Every 
dilution resulted in a 3-4 cycle difference in CT values (Fig. 14 B, Fig. 15 B, Fig. 16 B 
and Fig. 17 B). The melting curves for the respective targets also showed single melting  
peaks in all serially diluted samples (Fig. 14 C, Fig. 15 C, Fig. 16 C and Fig. 17 C). 
 
Fig. 14: (A) PCR efficiency curve for TH from rat adrenal gland. The PCR efficiency 
curved made by dilution series of adrenal gland showed 89.2% PCR efficiency, which is 
within acceptable limits. (B) Graph showing CTs from pure and serially diluted (1:10, 
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1:100 and 1:1000) cDNA samples. (C) A single melt peak was observed at all dilutions, 
confirming the specificity and efficiency of primer pairs. Temperature is plotted on the 
x-axis while -d(RFU)/dT, the difference in relative fluorescence units divided by 
difference in temperature, is plotted on the y-axis. 
Fig. 15: (A) PCR efficiency curve for DDC from rat adrenal gland. The PCR efficiency 
curved made by dilution series of adrenal gland showed 102.6% PCR efficiency, which 
is within acceptable limits. (B) Graph showing CTs from pure and serially diluted (1:10, 
1:100 and 1:1000) cDNA samples. (C) A single melt peak was observed at all dilutions, 
confirming the specificity and efficiency of primer pairs. Temperature is plotted on the 
x-axis while -d(RFU)/dT, the difference in relative fluorescence units divided by 
difference in temperature, is plotted on the y-axis. 
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Fig. 16: (A) PCR efficiency curve for DH from rat adrenal gland. The PCR efficiency 
curved made by dilution series of adrenal gland showed 104.5% PCR efficiency, which 
is within acceptable limits. (B) Graph showing CTs from pure and serially diluted (1:10, 
1:100, 1:1000 and 1:10000) cDNA samples. (C) A single melt peak was observed at all 
dilutions, confirming the specificity and efficiency of primer pairs. Temperature is 
plotted on the x-axis while -d(RFU)/dT, the difference in relative fluorescence units 
divided by difference in temperature, is plotted on the y-axis. 
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Fig. 17: (A) PCR efficiency curve for PNMT from rat adrenal gland. The PCR 
efficiency curved made by dilution series of adrenal gland showed 95.2% PCR 
efficiency, which is within acceptable limits. (B) Graph showing CTs from pure and 
serially diluted (1:10, 1:100, 1:1000 and 1:10000) cDNA samples. (C) A single melt 
peak was observed at all dilutions confirming the specificity and efficiency of primer 
pairs. Temperature is plotted on the x-axis while -d(RFU)/dT, the difference in relative 
fluorescence units divided by difference in temperature, is plotted on the y-axis. 
 
III.3.2 Real-time RT-PCR from rat arteries  
 The expression of mRNA for catecholamine synthesizing enzymes was studied 
in the rat thoracic and abdominal aorta, superior mesenteric artery and femoral artery by 
real-time RT-PCR. The mRNA expression of all of these four enzymes involved in 
catecholamine synthesis was detected by real-time RT-PCR using intron spanning 
specific primers. Amplicon sizes were 216 bp for TH, 221 bp for DDC, 162 bp for DH 
and 106 bp for PNMT and 252 bp for the house keeping gene -actin. The cleanliness 
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of PCR reaction was confirmed by running water control (water was added in place of 
cDNA) and reverse transcriptase control (no reverse transcriptase was added while 
making cDNA) which showed no product amplification and subsequent detection on 
agarose gel (Fig. 18). By using real-time RT-PCR, mRNA expression levels were also 
studied quantitatively. In each real-time RT-PCR experiment, melting curves were also 
analyzed. Each target, in each artery, showed only one peak in the melting curve, 
corresponding to a single PCR product amplified in that particular PCR reaction (Figs. 
19,20,21,22). 
 
Fig. 18: Agarose gel electrophoresis of real-time RT-PCR products for the 
catecholamine synthesizing enzymes. Sup. Mes. Art.: superior mesenteric artery; Fem. 
Art.: Femoral artery; Abd. Aorta: Abdominal aorta; Tho. Aorta: Thoracic aorta. The 
control reactions were carried out as ø RT control: without reverse transcription reaction 
and water control: water in place of cDNA template, which showed no PCR product 
amplification. 
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Fig. 19: Melting curves of real-time RT-PCR of catecholamine synthesizing enzymes 
from the real-time RT-PCR products from thoracic aorta, a representative picture for all 
the enzymes. In every experiment, each target was run in triplicate and showed a single 
peak in the melting curve. The peaks show the melting point of the amplified PCR 
product. Temperature is plotted on the x-axis while -d(RFU)/dT, the difference in 
relative fluorescence units divided by difference in temperature, is plotted on the y-axis.  
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Fig. 20: Melting curves of real-time RT-PCR of catecholamine synthesizing enzymes 
from the real-time RT-PCR products from abdominal aorta, a representative picture for 
all the enzymes. In every experiment, each target was run in triplicate and showed a 
single peak in the melting curve. The peaks show the melting point of the amplified 
PCR product. Temperature is plotted on the x-axis while -d(RFU)/dT, the difference in 
relative fluorescence units divided by difference in temperature, is plotted on the y-axis. 
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Fig. 21: Melting curves of real-time RT-PCR of catecholamine synthesizing enzymes 
from the real-time RT-PCR products from superior mesenteric artery, a representative 
picture for all the enzymes. In every experiment, each target was run in triplicate and 
showed a single peak in the melting curve. The peaks show the melting point of the 
amplified PCR product. Temperature is plotted on the x-axis while -d(RFU)/dT, the 
difference in relative fluorescence units divided by difference in temperature, is plotted 
on the y-axis. 
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Fig. 22: Melting curves of real-time RT-PCR of catecholamine synthesizing enzymes 
from the real-time RT-PCR products from femoral artery, a representative picture for all 
the enzymes. In every experiment, each target was run in triplicate and showed a single 
peak in the melting curve. The peaks show the melting point of the amplified PCR 
product. Temperature is plotted on the x-axis while -d(RFU)/dT, the difference in 
relative fluorescence units divided by difference in temperature, is plotted on the y-axis. 
 
Real-time RT-PCR was used to compare expression levels of these four 
enzymes involved in catecholamine synthesis in these arteries. In the thoracic aorta, TH 
was significantly higher expressed as compared to DDC, DH and PNMT. In the 
abdominal aorta, TH expression was significantly higher than PNMT and DH 
expression. In the superior mesenteric artery, PNMT expression was highly significantly 
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lower than that of DDC and PNMT, while DH was stronger expressed than DDC. In 
the femoral artery, TH, DDC and DH expression were highly significantly stronger 
than PNMT expression (Fig.  23). 
 
Fig. 23: Box plots showing the delta CT values of the mRNA expression of 
catecholamine synthesizing enzymes in different arteries. A high delta CT value means 
that the gene is relatively low expressed, while a low delta CT value corresponds to a 
high expression of that particular gene. Data are presented as box plots with percentiles 
0, 25, 50 (median, indicated by horizontal line within the box) 75 and 100. Data was 
analyzed statistically by the non-parametric Kruskal-Wallis test and, if P0.05, further 
analysis among the groups was performed by Mann-Whitney test. Significance level 
was set as P0.05 (significant:), P0.01 (highly significant:) and P0.001 (very 
highly significant:). The symbol “” represents an outlier value. 
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In a next step, differences in enzyme expression between arteries were 
evaluated. TH mRNA expression was not significantly different between all the arteries. 
DDC mRNA expression was lowest in the thoracic aorta, being significantly different 
from the femoral and superior mesenteric artery. DH mRNA expression was lowest in 
the thoracic aorta. PNMT expression was significantly higher in the thoracic aorta than 
in the superior mesenteric artery and femoral artery (Fig. 24) 
 
Fig. 24: Box plots showing the delta CT values of the mRNA expression of 
catecholamine synthesizing enzymes in different arteries. A high delta CT value means 
that the gene is relatively low expressed, while a low delta CT value corresponds to a 
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high expression of that particular gene. Data are presented as box plots with percentiles 
0, 25, 50 (median, indicated by horizontal line within the box) 75 and 100.  Data was 
analyzed statistically by Kruskal-Wallis test and, if P0.05, further analysis with the 
groups was performed by Mann-Whitney test. Significance level was set as P0.05 
(significant:), P0.01 (highly significant:) and P0.001 (very highly 
significant:). The symbol “” represents an outlier value.  
III.3.3 Rat lung EC  
 Rat lung EC were investigated for the expression of mRNA for TH, DDC, DH, 
and PNMT. All of the four enzymes involved in catecholamine synthesis were detected 
in rat lung EC. The amplified PCR products were detected by agarose gel 
electrophoresis (Fig. 25), amplicon sizes were 216 bp for TH, 221 bp for DDC, 162 bp 
for DH and 106 bp for PNMT. The house keeping genes 2-MG 191 bp and -actin 
252 bp were also detected on the gel. 
 
Fig. 25: RT-PCR for the catecholamine synthesizing enzymes in lung EC, agarose gel 
electrophoresis. The control reactions were carried out as ø RT ctrl.: without reverse 
transcription reaction and water ctrl.: water in place of cDNA template, which showed 
absence of PCR product amplification. 
 
The lungs EC were exposed to hypoxia (1% O2) for 6, 12 and 24 hours, and a 
control was maintained at normoxic condition (21% O2). Real-time PCR was performed 
and melting curves were analyzed showing specificity of PCR reaction and no 
amplification of unspecific products (Fig. 26). 
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Fig. 26: Melting curves of real-time RT-PCR of catecholamine synthesizing enzymes 
from the rat lung EC, representative picture for all the enzymes. In each experiment, 
each target was run in triplicate and showed only a single peak. The peaks show the 
melting point of the amplified product. Temperature is plotted on the x-axis while -
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d(RFU)/dT, the difference in relative fluorescence units divided by difference in 
temperature, is plotted on the y-axis.  
 
 
Hypoxia caused an up-regulation in TH mRNA expression by 25-fold after 24 
hours of exposure. There was no significant difference in DDC mRNA expression (Fig. 
27). 
 
 
Fig. 27: Effect of hypoxia on the expression of TH and DDC mRNA in rat lung EC. 
There was a highly significant increase in TH mRNA expression after 24 h of hypoxic 
exposure, while there was no significant change in DDC mRNA expression. Data are 
presented as box plots with percentiles 0, 25, 50 (median, indicated by horizontal line 
within the box) 75 and 100.  Data was analyzed statistically by Kruskal-Wallis test and, 
if P0.05, further analysis with the groups was performed by Mann-Whitney test. 
Significance level was set as P0.05 (significant:), P0.01 (highly significant:) and 
P0.001 (very highly significant:). The symbol “” represents an outlier value.  
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DH mRNA expression was upregulated after 6 and 24 h of hypoxic exposure 
as compared to normoxia (Fig. 28). 
 
Fig. 28: Effect of hypoxia on the expression of DH mRNA in rat lung EC. There was a 
highly significant increase in DH mRNA expression after 6 and 24 h of hypoxic 
exposure. Data are presented as box plots with percentiles 0, 25, 50 (median, indicated 
by horizontal line within the box) 75 and 100.  Data was analyzed statistically by 
Kruskal-Wallis test and, if P0.05, further analysis with the groups was performed by 
Mann-Whitney test. Significance level was set as P0.05 (significant:), P0.01 (highly 
significant:) and P0.001 (very highly significant:). The symbol “” represents an 
outlier value.  
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There was no significance change in PNMT mRNA expression after hypoxic 
exposure (Fig. 29). 
 
 
Fig. 29: Effect of hypoxia on the expression of PNMT mRNA in rat lung EC. There was 
no significance change in PNMT mRNA expression after hypoxic exposure. Data are 
presented as box plots with percentiles 0, 25, 50 (median, indicated by horizontal line 
within the box) 75 and 100. The symbol “” represents an outlier value.  
III.3.4 Rat aortic EC 
The EC from rat aorta were investigated for the expression of mRNA for TH, 
DDC, DH, and PNMT. All of the four enzymes involved in catecholamine synthesis 
were detected in RT-PCR. The amplified PCR products were detected by agarose gel 
electrophoresis (Fig. 30), amplicon sizes were 216 bp for TH, 221 bp for DDC, 162 bp 
for DH and 106 bp for PNMT. The house keeping genes 2-MG 191 bp and -actin 
252 bp were also detected on the gel. 
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Fig. 30: RT-PCR for the catecholamine synthesizing enzymes from rat aortic EC, 
agarose gel electrophoresis. M: base pair marker. The control reactions were carried out 
as ø RT ctrl.: without reverse transcription reaction, and water ctrl.: water in place of 
cDNA template, which showed absence of PCR product amplification. In case of water 
and RT control for 2-MG, a weak single band is visible which is caused by primer 
dimers. 
 
Aortic EC were exposed to hypoxia (1% O2) for 6, 12 and 24 hours and a control 
was maintained at normoxic condition (21% O2). Total RNA was isolated from 
normoxic and hypoxic cells and the cDNA was synthesized. Real-time PCR was 
performed and melting curves were analyzed, showing specificity of PCR reaction and 
no amplification of unspecific products (Fig. 31). 
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Fig. 31: Melt curves of real-time RT-PCR of catecholamine synthesizing enzymes from 
the rat aortic EC, a representative picture for all the enzymes. In each experiment, each 
target was run in triplicate and shows no extra peaks. Peak shows the melting point of 
the amplified product. Temperature is plotted on the x-axis while -d(RFU)/dT, the 
difference in relative fluorescence units divided by difference in temperature, is plotted 
on the y-axis. 
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Hypoxic exposure did not cause a significant change in the mRNA expression of 
the enzymes involved in catecholamine synthesis (Fig. 32). 
 
 
 
Fig. 32: Effect of hypoxia on the expression of TH, DDC, DH and PNMT mRNA in 
rat aortic EC. There was no significance difference in mRNA expression of any of the 
enzymes after hypoxic exposure for 6, 12 and 24 h. Data are presented as box plots with 
percentiles 0, 25, 50 (median, indicated by horizontal line within the box) 75 and 100. 
Data was analyzed statistically by Kruskal-Wallis test, significance was set as P 0.05. 
The symbol “” represents an outlier value. 
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III.3.5 Rat aortic smooth muscle cells 
Rat aortic smooth muscle cells (thoracic and abdominal aorta) were investigated 
for the expression of mRNA for TH, DDC, DH, and PNMT.  All mRNAs were readily 
detectable except that for DDC. The amplified PCR products were detected by agarose 
gel electrophoresis (Fig. 33), amplicon sizes were 216 bp for TH, 221 bp for DDC, 162 
bp for DH and 106 bp for PNMT. The house keeping genes 2-MG (191 bp) and -
actin (252 bp) were also detected on the gel. 
 
Fig. 33: Real-time RT-PCR for the catecholamine synthesizing enzymes from rat 
thoracic aortic smooth muscle cells, agarose gel electrophoresis. M: base pair marker. 
The control reactions were carried out for TH, as ø RT ctrl. without reverse transcription 
reaction and water ctrl. water in place of cDNA template, which showed no PCR 
product amplification. 
 
Aortic smooth muscle cells were exposed to hypoxia (1% O2) for 6, 12 and 24 
hours and a control was maintained at normoxic condition (21% O2). Real-time PCR 
was performed and melting curves were analyzed, showing specificity of PCR reaction 
and no amplification of unspecific products (Figs. 34 & 35). 
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Fig. 34: Melting curves of real-time RT-PCR of catecholamine synthesizing enzymes 
from the rat thoracic aortic smooth muscle cells, a representative picture. In each 
experiment, each target was run in triplicate and shows no extra peaks. The peaks show 
the melting point of the amplified PCR product. Temperature is plotted on the x-axis 
while -d(RFU)/dT, the difference in relative fluorescence units divided by difference in 
temperature, is plotted on the y-axis. 
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Fig. 35: Melting curves of real-time RT-PCR of catecholamine synthesizing enzymes 
from the rat abdominal aortic smooth muscle cells, a representative picture. In each 
experiment, each target was run in triplicate and shows no extra peaks. The peaks show 
the melting point of the amplified PCR product. Temperature is plotted on the x-axis 
while -d(RFU)/dT, the difference in relative fluorescence units divided by difference in 
temperature, is plotted on the y-axis. 
 
In thoracic aortic smooth muscle cells, hypoxic exposure did not cause a 
significant change in the mRNA expression of DH and PNMT (Fig. 36). The 
expression of TH and DDC mRNA was too low to be quantified, although TH was 
qualitatively detectable (Fig. 33). 
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Fig. 36: Effect of hypoxia on the expression of DH and PNMT mRNA in rat thoracic 
aortic smooth muscle cells. There was no significance difference in mRNA expression 
of any of the enzymes after hypoxic exposure for 6, 12 and 24 h. Data are presented as 
box plots with percentiles 0, 25, 50 (median, indicated by horizontal line within the box) 
75 and 100. Data was analyzed statistically by Kruskal-Wallis test. Significance level 
was set as P 0.05. 
 
In abdominal aortic smooth muscle cells, hypoxic exposure did not cause a 
significant change in the mRNA expression of DH and PNMT (Fig. 37). The 
expression of TH and DDC mRNA was too low to be quantified, although TH was 
qualitatively detectable (Fig. 33). 
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Fig. 37: Effect of hypoxia on the expression of DH and PNMT mRNA in rat 
abdominal aortic smooth muscle cells. There was no significance difference in mRNA 
expression of any of the enzymes after hypoxic exposure for 6, 12 and 24 h. Data are 
presented as box plots with percentiles 0, 25, 50 (median, indicated by horizontal line 
within the box) 75 and 100. Data was analyzed statistically by Kruskal-Wallis test. 
Significance level was set as P 0.05. 
III.3.6 Catecholamine synthesis in human cells 
To study catecholamine synthesizing in human cells, intron spanning primer 
pairs were designed and PCR conditions were optimized by using cDNA from a 
pheochromocytoma. Single peaks in the melting curves indicated specific PCR product 
amplification (Fig. 38). This was further confirmed by agarose gel electrophoresis (Fig. 
39). All the four mRNAs coding for catecholamine synthesis enzymes were detected in 
the gel. Amplicon sizes were 138 bp for TH, 222 bp for DDC, 157 bp for DH, 281 bp 
for PNMT, and 160 bp for the housekeeping gene 2-MG. 
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Fig. 38: Melting curves from cDNA of a human pheochromocytoma subjected to PCR, 
a representative picture for catecholamine synthesizing enzyme. In each experiment, 
each target was run in duplicate and showed only a single melting peak. The peaks show 
the melting point of the amplified PCR product. Temperature is plotted on the x-axis 
while -d(RFU)/dT, the difference in relative fluorescence units divided by difference in 
temperature, is plotted on the y-axis. 
 
Fig. 39: Real-time RT-PCR for the catecholamine synthesizing enzymes from a 
pheochromocytoma, agarose gel electrophoresis. M: base pair marker.  
 
  As an additional positive control, real-time RT-PCR was run from a human 
sympathetic trunk ganglion. All the four mRNAs coding for catecholamine synthesis 
enzymes were detected in the gel, except for PNMT which was not detectable (Fig. 40), 
much in line with the inability of principal sympathetic neurons to convert 
noradrenaline into adrenaline. 
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Fig. 40: Real-time RT-PCR for the catecholamine synthesizing enzymes from human 
sympathetic trunk, agarose gel electrophoresis. M: base pair marker. The control 
reactions were carried out for TH, as ø RT ctrl. without reverse transcription reaction) 
and water ctrl. water in place of cDNA template, which showed absence of PCR product 
amplification. 
  
Primary HAEC, HMVEC-L, HPAEC and HAoSMC were purchased from 
Lonza, cultured and characterized. These cells were exposed to hypoxia (1% O2) for 6, 
12 and 24 h, and to normoxia (21% O2). In real-time RT-PCR, mRNA of none of the 
enzymes was detected. Only the house keeping gene 2-MG (amplicon size: 160 bp) 
was detectable, showing the functionality of PCR conditions (Fig. 41). 
Fig. 41: Real-time RT-PCR for the catecholamine synthesizing enzymes from HMVEC-
L, agarose gel electrophoresis. M: base pair marker. The control reactions were carried 
out, as “ø RT ctrl.” without reverse transcription reaction, and “water ctrl.” water in 
place of cDNA template, which showed absence of PCR product amplification. 
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IV Discussion 
IV.1 Non-neuronal catecholamine synthesis in arteries 
Catecholamines (dopamine, norepinephrine and epinephrine) play a vital role in 
the regulation of various body functions by the nervous system. Dopamine is a 
transmitter in the CNS, norepinephrine in the CNS and of postganglionic sympathetic 
neurons, and epinephrine is both a hormone released from the adrenal gland and also 
serves as neurotransmitter of brain stem neurons. Still, they are not restricted to the CNS 
(Kuhar et al., 2006). The present study elaborated on the synthesis and hypoxic 
regulation of catecholamines in vascular cells with particular reference to dopamine, 
which might act as local vasodilator. 
Vascular tone of peripheral arteries, (e.g. SMA) is mediated by three types of 
nerve fibers innervating the vascular wall: sympathetic nerve fibers (releasing NE and 
causing vasoconstriction), parasympathetic nerve fibers (cholinergic fibers and nitregic 
fibers, causing vasodilation) and sensory fibers (C-fibers releasing substance P and 
calcitonin gene-related peptide, causing vasodilation) (Morris et al., 1995). Furthermore 
other factors such as circulating and locally produced hormones, e.g. bradykinin, also 
play an important role in the regulation of vascular tone (Auch-Schwelk et al., 1993). 
Little is known about catecholamine synthesis within the vascular wall, which is 
mainly composed of ECs, VSMC and adventitial connective tissue cells. This is the first 
study providing a detailed evidence of catecholamine synthesis within the vascular wall. 
In the present study, expression of mRNA of all of four enzymes of the catecholamine 
synthesis pathway was detected and quantified in rat thoracic and abdominal aorta, 
SMA and femoral artery. It was observed that these arteries express different levels of 
mRNA of these enzymes. TH is the rate limiting enzyme of the pathway which converts 
L-tyrosine to L-DOPA (Nagatsu et al., 1964); its mRNA is highly expressed in all of 
these arteries. TH protein was also detected in these arteries by immunolabelling and 
western blot analysis. TH mRNA and protein expression in these arteries suggests 
active synthesis of dopamine and/or other catecholamines in these vessels. TH mRNA 
expression and enzyme activity have been already been reported in 1999 in various non-
neuronal and non-adrenal tissues of rat, e.g. aorta, vas deferens, stomach, lung, 
duodenum, pancreas, spleen and salivary gland (Kawamura et al., 1999). After chemical 
sympathectomy (6-hydroxydopamine) of young adult rats, catecholamine levels (NE, 
dopamine), TH mRNA and enzyme activity were reduced in most organs such as vas 
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deferens, stomach and salivary gland whereas they remained unchanged in the 
abdominal aorta. This persistence of catecholamines and their synthesizing enzyme in 
the aorta was interpreted by the authors as being due to the presence of sympathetic 
nerve cell bodies or extra-adrenal paraganglia, e.g. organ of Zuckerkandl (Kawamura et 
al., 1999). The present study, however, clearly demonstrates non-neuronal and non-
paraganglionic sources of TH in the arterial wall, since 1) this enzyme was consistently 
found also in arteries that are not accompanied by paraganglia (e.g. femoral artery and 
thoracic descending aorta), 2) paraganglia were never observed in the specimens 
processed for immunohistochemistry, and 3) TH mRNA and protein were also detected 
in cultured cells from the vascular wall, i.e. EC and VSMC. 
DDC is the second enzyme of the catecholamine synthesis pathway. DDC 
mRNA expression, as well as that of DH mRNA, was lower in the thoracic aorta than 
in the other arteries investigated in the present study. These quantitative differences 
might suggest less active synthesis of catecholamines in this particular arterial segment. 
However, there are no direct data addressing this issue and it is noteworthy that no 
significant differences were observed in expression of the rate limiting enzyme, TH. 
Structurally, the thoracic aorta differs from the other arteries being investigated in this 
study by its highly elastic wall. Generally, there are two types of arteries: elastic and 
conducting arteries. The highly elastic wall of arteries close to the heart allows them to 
store part of the ejected volume during systole and maintain blood flow at diastole. The 
VSMC of these arteries synthesize elastin and other extracellular matrix components 
and are classified as metabolic VSMC. The tunica media of distributing or muscular 
arteries, is mainly composed of SMC of the contractile type and these arteries are 
mainly involved in the regulating the distribution of blood to various organs according 
to physiological needs, e.g. low pO2 causes vasodilation to accommodate more blood 
supply to the organ. The differences in DDC and DH mRNA content observed in the 
present study might reflect differences in catecholamine synthesis by metabolic and 
contractile VSMC although this has further to be confirmed by direct investigation. 
NE and E are synthesized by the actions of DH and PNMT. Messenger RNAs 
coding for both of these enzymes were also consistently detected in all arteries in this 
study. Expression of DH and PNMT within the vascular wall suggests local synthesis 
of NE and E. Supportively, NE and E levels are largely reduced in chemically 
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sympathectomized aorta and SMA but 20% still persisted in our accompanying 
experiments (Kuncová et al., 2007).  
Non-neuronal NE and E have also been reported in the heart. In the human heart, 
NE has been reported to account for 88% out of total synthesized catecholamines, 
whereas the balance of 12 % is dopamine (Eisenhofer et al., 1997). On the other hand, 
the human heart contains also PNMT protein and activity (Kennedy et al., 1995). In the 
rat heart, there is significant expression of PNMT also. Here, PNMT mRNA expression 
persists after chemical sympathectomy, and immunofluorescence identified 
cardiomyocytes as a source of this non-neuronal PNMT (Kvetnanský et al., 2006). 
PNMT is predominantly present in brain and adrenal gland (Ziegler et al, 2002). 
This enzyme has also been previously reported to be present in various non-neuronal 
organs, e.g. spleen (Pendleton et al., 1978), lung (Pendleton et al., 1978; Kennedy et al., 
1990), kidney (Ziegler et al., 1989), and heart (Axelrod, 1962; Pendleton et al., 1978; 
Kennedy and Ziegler, 1991; Eisenhofer et al., 1997). In the present study of arteries, 
PNMT mRNA content was significantly lower than that of the other enzymes which 
also fits to our observation that, after sympathectomy, vascular E levels were lowest 
among the catecholamines (Kuncová et al., 2007). 
Collectively, the present data demonstrate that the machinery for synthesis of 
non-neuronal catecholamine, predominantly dopamine and synthesis occurs also in 
intact arteries where these locally synthesized catecholamines might play an important 
role in various vascular functions. 
IV.2 Expression and regulation of catecholamine synthesizing enzyme mRNAs in 
vascular cells 
The dominant cells of vascular intima and media are EC and VSMC, 
respectively. EC are present on the inner most surfaces and form a monolayer of flat and 
compactly packed cells. They play a vital role in vascular injury repair mechanisms and 
help to maintain the vascular tone and hemostasis. EC release different mediators in 
response to various stimuli, e.g. vWF, prostaglandins, growth factors, cytokines and 
nitric oxide (Augustin, 2007). VSMC are the contractile end-effectors of the vascular 
wall, which receive input from the endothelium and also from the nervous system. They 
regulate the vascular diameter according to the inputs. Furthermore, they are also 
involved in the synthesis and secretion of extracellular matrix which also plays an 
important role in vascular function (Handa et al., 2007).  
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This is the first study providing evidence of expression of catecholamine 
synthesis enzymes in isolated vascular cells. Under normoxic conditions, EC express 
mRNAs coding for all of the enzymes involved in catecholamine synthesis. In rat 
pulmonary EC, hypoxia caused an up-regulation of TH mRNA by 25-fold after 24 h, of 
DH mRNA by 8-fold after 6 and 24 h, whereas DDC and PNMT mRNA content were 
not significantly different after hypoxic exposure. Other studies have also shown up-
regulation of TH mRNA expression after hypoxic exposure. Hypoxia causes up-
regulation of TH mRNA transcription, and this effect can be inhibited by protein kinase 
C inhibitors (Millhorn et al., 1997; Raymond and Millhorn, 1997). It has been shown 
that TH mRNA expression is up-regulated by hypoxia in cultured rat mesencephalic 
cells by 4-5 fold, and dopamine content was also increased by 5-fold (Leclere et al., 
2004). In PC12 cells, a rat pheochromocytoma cell line, TH and PNMT mRNA and 
protein expression are up-regulated in response to hypoxia (Czyzyk-Krzeska et al., 
1994; Norris and Millhorn, 1995; Höhler et al., 1999; Evinger et al., 2000). The duration 
of hypoxia also plays an important role on the expression and stability of TH mRNA. It 
has been reported that the rate of TH mRNA transcription increases rapidly after 
hypoxic exposure with peak levels at ~6 h. This higher expression is maintained over a 
time period of >12 h in PC12 cells (Czyzyk-Krzeska et al., 1994). 
In contrast to the reported hypoxic regulation of TH expression in several cell 
types including rat pulmonary EC in the present study, hypoxic exposure of rat aortic 
EC did not cause a significant change in the mRNA expression of any of these enzymes. 
It remains to be determined whether this reflects different properties of the systemic 
versus pulmonary circulation or microvascular - the isolation procedure of lung EC 
favors enrichment of microvascular EC - versus arterial EC. 
Rat aortic VSMC also express the mRNAs for TH, DH and PNMT while DDC 
mRNA expression was too low to be detected in these cells. This apparent lack or 
paucity of DDC might imply that L-DOPA instead of catecholamines is the major 
product in VSMC. Alternatively, synthesis may proceed towards dopamine via low 
levels of DDC below detection level of the present approach, or by DDC from other 
sources. 
L-DOPA from VSMC might be taken up by EC to be converted to dopamine. L-
type amino acid transporters are likely candidates for accomplishing this release and 
uptake. Rat brain EC have a sodium independent L-type amino acid transporter (LAT) 
which is involved in the transport of L-DOPA from blood stream to the neurons 
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(Sampaio-Maia et al., 2001). This transporter is reported to work as importer and 
exporter of L-DOPA. Such transporter is also reported in EC of other parts of the 
vascular tree such as rat retinal microvasculature (Tomi et al., 2005) and human aorta 
(Haase et al., 2007).  
L-DOPA might act as a regulator of dopamine synthesis in EC. In the previous 
years it has been shown that externally applied L-DOPA can increase the dopamine 
synthesis rate and activity of DDC. It has been shown that treatment of PC12 cells with 
L-DOPA (20-200 µM) results in increased dopamine synthesis by 226-504% by 
increasing the enzymatic activity of TH and DDC (Jin et al., 2008).  
DH and PNMT mRNA expression indicates that VSMCs are capable of NE 
and E synthesis. Dopamine released from EC might serve as a substrate for DH and 
PNMT in VSMC. In addition, DDC also circulates in plasma (Boomsma et al., 1986; 
Lee et al., 1986), so that sufficient L-DOPA converting activity in the vascular wall can 
be assumed. In this scenario, conversion of dopamine into NE by VSMC requires 
dopamine uptake. Several dopamine transporters are known, among them being most 
important the plasma monoamine transporter PMAT (Okura et al., 2011), the dopamine 
transporter (DAT) (Mignini et al., 2006), and organic cation transporter-2 (OCT-2) 
(Gründemann et al., 1998). While plasma monoamine transporter (PMAT) and DAT are 
considered to be preferentially expressed in the nervous system, DAT immunoreactivity 
in arterial walls also has been reported (Mignini et al., 2006). Detailed studies on 
potential dopamine transporters in VSMC have not been reported yet.  
This locally synthesized NE and E might also play an important role in 
physiological functions of VSMC or the vascular wall in general, but unlike 
catcholamine synthesis in various other cells including pulmonary EC, synthesis 
appears not to be significantly regulated by hypoxia and indicated from the present real-
time RT-PCR experiments.  
Collectively, these data indicated that there are two sources of catecholamines - 
neuronal and non-neuronal - in the vascular wall, with the non-neuronal catecholamine 
synthesis not being restricted to a single cell type. In addition to EC and VSMC directly 
addressed in the present study, various cells of the immune system are also regular 
constituents of the vascular wall, and they provide additional sources of intrinsic non-
neuronal catecholamines (Flierl et al., 2007). 
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IV.2.1 Expression in human vascular cells 
The data obtained from human vascular cells differed considerably from those of 
isolated vascular cells from rat. None of the four enzymes were detectable by PCR from 
cDNA of human vascular cells, despite the housekeeping gene (2-MG) was readily 
detected, proving efficiency of RNA isolation and reverse transcription. We had 
optimized the PCR conditions for the primer pairs addressing catecholamine 
synthesizing enzymes by using total RNA from human pheochromocytoma. Human 
pheochromocytomas express high levels of mRNA of TH, DDC and DH while mRNA 
for PNMT is lower as compared to healthy persons (Isobe et al., 1998). In our 
pheochromocytoma sample we were able to detect mRNA of TH, DDC and DH by 
using RT-PCR, suggesting that our primer pairs and PCR conditions are well optimized. 
In order to further support our results we used total RNA from human sympathetic trunk 
as another positive control. Again, all four enzyme mRNAs were detectable by using 
the same primer pairs as were used for human vascular cells.  
In human brain, four splice variants for human TH are reported while in rodent 
only one variant exists and there are 2 variants in monkey (Lewis et al., 1993). In this 
study, primer pairs were selected to be able to detect any of the four human variants. 
Thus, the negative results in human vascular cells are unlikely to be explained by 
presence of an unusual splice variant. 
Consequently, the most likely explanation for the negative findings is that 
cultured human vascular cells do not express the classical catecholamine synthesizing 
enzymes. It has to be considered that these human vascular cells were purchased from a 
commercial provider using different isolation protocols than we used for isolation of rat 
cells. However, even when TH, DDC, DH and PNMT are indeed not expressed in 
human vascular cells, this does not rule out the possibility of catecholamine synthesis by 
these cells. An alternative pathway for the catecholamine synthesis has also been 
reported, mediated by an enzyme tyrosinase, mainly present in melanocytes, which can 
convert tyrosine to L-DOPA. This L-DOPA can be released and can be taken up by 
other cells expressing DDC to make dopamine (Sanchez-Ferrer et al., 1995).  
IV.3 Catecholamines, hypoxia and vasodilation 
Catecholamines function as neurotransmitters and neuro-hormones and play an 
important role in the regulation of various physiological and metabolic processes in 
68 
 
body. All three catecholamines (E, NE and dopamine) are found in plasma. Plasma NE 
originates from sympathetic neuronal activity while E mainly comes from the adrenal 
medulla, whereas plasma dopamine content has been ascribed to originate mainly from 
sympathetic noradrenergic nerve terminals (Goldstein and Holmes, 2008). These 
circulating catecholamines might play important role in various physiological functions. 
In clinical practice dopamine is administered in acute hypotension illness. At low dose, 
dopamine acts on vascular -adrenergic and dopamine receptors while at high doses it 
also stimulates 1 and 2 adrenergic receptors. Low dose dopamine has many beneficial 
effects; it increases cardiac output and heart rate and selectively increases the blood 
flow in renal and hepato-splanchnic arteries, decreases pulmonary resistance and 
enhances oxygen supply (Hoffman et al., 1990; Philip-Joet et al., 1988; Chan, 1995). 
The body responds to hypoxia by increasing the hyperventilation (acute) and by 
polycythemia (chronically) by increased production of red blood cells, to enhance the 
O2 carrying capacity of blood. Hyperventilation is mediated by the carotid body 
chemoreceptors. The type I cells of carotid body are reported to be O2 sensitive and 
release dopamine in the event of low pO2. During hypoxia, TH enzymatic activity and 
expression is also increased in these cells (Czyzyk-Krzeska et al., 1994).  
In parallel studies (Kuncová et al., 2007), we have observed that lowering of pO2 
causes vasodilation in isolated and perfused rat SMA. This vasodilator response is 
blocked by the D1 receptor agonist SCH-23990, suggesting an endogenous release of 
dopamine in the vascular wall. After removal of the endothelial cell layer, this 
vasodilator response is still present, although less than with an intact endothelial cell 
layer, and still can be blocked by the D1 receptor agonist SCH-23990. It is well known 
that smooth muscle cells express dopamine receptors D1 and D3. Dopamine acts via D1 
and D3 receptors located on rat mesenteric artery smooth muscle cells. Furthermore, 
these receptors interact physically and are probably involved in regulation of blood 
pressure and flow in this artery (Zeng et al., 2004). Vasodilation by D1 receptors is 
mediated by cAMP/PKA signaling pathway. Stimulation of these receptors also 
increases intracellular levels of cAMP (Hussain and Lokhandwala, 1998; Jose et al., 
1998; Jose et al., 2002). 
The observations on endothelial denuded SMA support the hypothesis that there 
are two sources of dopamine in the vascular wall: EC and SMC. This conclusion derives 
from the finding that D1 receptor mediated hypoxic relaxation was diminished but not 
abolished by removal of the endothelium. The current work also supports this, as EC 
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express mRNA of all of the four enzymes, and under hypoxic conditions regulation for 
TH and DH mRNAs was also observed. The rat VSMC expresses mRNAs for TH, 
DH and PNMT while DDC mRNA expression was too low to be detected. It already 
has been discussed that they still may possess the ability of catecholamine synthesis by 
up-take of dopamine. The same transporters that mediate uptake of dopamine, i.e. 
PMAT, DAT and OCT-2 (Gründemann et al., 1998; Mignini et al., 2006; Okura et al., 
2011), can also serve as release mechanisms. In rat endothelial cell lines and brain 
capillaries, PMAT expression has recently been reported (Okura et al., 2011) but more 
studies are needed to elucidate endothelial dopamine release mechanisms in more detail. 
IV.4 Other non-neuronal functions of dopamine  
Recently it has been reported that catecholamines are involved in a broader 
variety of physiological and pathophysiological functions than previously thought. New 
evidences are emerging that they are synthesized by other tissues or cells in the body 
having diverse functions. Catecholamine synthesis in the gastrointestinal tract is well 
reported (Eisenhofer et al., 1997) and it is suggested that in catecholamines are probably 
involved in exocrine secretion from the pancreas (Iwatsuki et al., 1992), bicarbonate 
secretion regulation in stomach and duodenum (Flemstrom et al., 1993). The pancreas is 
reported to be actively involved particularly in dopamine synthesis and release; the 
dopamine is usually released into the duodenum along with other secretions. It is 
postulated that dopamine acts as a self defense mechanism in the gastrointestinal tract 
against harmful agents (Mezey et al., 1996). 
Tumor hypoxia is an important feature of advanced solid tumors (Vaupel and 
Harrison, 2004). It has been reported that tumor cells can synthesize dopamine under 
hypoxic conditions thereby decreasing angiogenesis by acting in a paracrine manner via 
D2 receptors located on EC of the tumor vessels (Basu et al., 2001; Chakroborty et al., 
2008). The expression of dopamine synthesis machinery and its hypoxic regulation in 
vascular cells might be an indigenous protective mechanism to prevent tumor invasion 
and metastasis. 
Dopamine is also reported to modulate the exocytosis in EC in response to 
thrombin or histamine by inhibiting the release of vWF (Zarei et al., 2006). Immune 
cells are also reported to be equipped with catecholamine synthesizing machinery. 
Particularly, monocytes are reported to be able to synthesize and release catecholamines 
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(Cosentino et al., 1999; Brown et al., 2003). This synthesis and release is increased in 
response to inflammatory mediators such as LPS in alveolar macrophages and blood 
monocytes (Flierl et al., 2007). 
Finally, it also has to be considered that dopamine might not only act via 
dopamine receptors but also can be converted into other active, non-catecholaminergic 
compounds. N-Arachidonoyl-dopamine is an endocannabinoid that acts as a vasodilator 
through vanniloid and cannabinoid receptors (O’Sullivan et al., 2004).  
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V Conclusions 
Endothelial cells express the enzymatic machinery for catecholamine synthesis 
and, upon hypoxia or low pO2, this machinery is activated and produces dopamine and 
possibly other catecholamines, too. The locally synthesized dopamine stimulates the D1 
receptors on underlying smooth muscle cells, causing relaxation/vasodilation, ultimately 
resulting in increased blood supply to affected organ. Smooth muscle cells also have the 
machinery to synthesize NE and E once dopamine is provided. Possibly, they can take 
up dopamine from EC via membrane transporters. Upon lowered pO2, this stored 
dopamine is released and acts on dopamine receptors on smooth muscle cells and results 
in vasodilation (Fig. 42). 
 
Fig. 42: Proposed scenario of regulation of catecholamine synthesis in vascular cells. 
DT: dopamine transport mechanisms, e.g. PMAT, DAT or OCT-2, 
DA: Dopamine 
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VII Summary 
 Catecholamines (dopamine, norepinephrine and epinephrine) are physiologically 
important as they are involved in a number of body functions and also act as 
neurotransmitters. Dopamine is a metabolic intermediate in the formation of 
norepinephrine and epinephrine and a well known neurotransmitter in the central 
nervous system. In most of the mammalian systemic arteries, dopamine acts as a potent 
vasodilator. The vascular effects of dopamine are mediated via specific G protein-
coupled receptors (D1-D5). 
 The present study aimed to look for the presence of enzymatic machinery 
(tyrosine hydroxylase = TH; DOPA-decarboxylase = DDC; dopamine-β-hydroxylase = 
DβH; phenylethanolamine-N-methyltransferase = PNMT) required to synthesize 
catecholamines in rat arteries, and their regulation in response to hypoxia (1% O2) in 
endothelial (EC) and vascular smooth muscle cells (VSMC). Quantitative RT-PCR 
served to estimate mRNA content, and western blotting was used to test for TH protein 
expression. Furthermore, we also looked for the expression of the rate-limiting enzyme 
of catecholamine synthesis, TH, by quantitative RT-PCR, immunohistochemistry and 
western blotting in the intact vessels (rat thoracic aorta, abdominal aorta, superior 
mesenteric artery [SMA] and femoral artery).  
 Expression of mRNA of all four enzymes of the catecholamine synthesis 
pathway was detected and quantified in rat thoracic and abdominal aorta, SMA and 
femoral artery. It was observed that these arteries express different levels of mRNA 
content of these enzymes with PNMT being least abundant. TH protein was also 
detected in these arteries by immunolabelling and western blot analysis. TH expression 
in these arteries suggests active synthesis of dopamine and/or other catecholamines in 
these vessels. Previously, TH mRNA expression has been reported in rat aorta and it has 
been suggested that this might be the result of paraganglia contamination during 
sampling process. No paraganglia were detectable in immunohistochemical preparation 
of rat aorta suggesting that this part of vascular tree is itself capable of synthesizing 
catecholamines. 
 Rat pulmonary and aortic EC were isolated and cultured. These cells were 
characterized by DiI-Ac-LDL uptake and by immunolabeling with anti-vWF antibody. 
VSMC were isolated and cultured from thoracic and abdominal aorta and characterized 
by immunolabeling with anti α-smooth muscle actin antibody. Under normoxic 
conditions, EC and VSMC express mRNAs coding for all of the enzymes involved in 
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catecholamine synthesis. These vascular cells were exposed to hypoxia (1% O2) for 6, 
12 and 24 hours. Using real-time RT-PCR we detected the mRNAs for the complete or 
partial enzymatic machinery necessary for catecholamine synthesis in these cells. In rat 
pulmonary EC, hypoxia caused an up-regulation of TH mRNA by 25-fold after 24 h, of 
DβH mRNA by 8-fold after 6 and 24 h, whereas DDC and PNMT mRNA content were 
not significantly different after hypoxic exposure. In contrast, no significant effect of 
hypoxia on the regulation of the enzymatic machinery was observed in rat aortic EC. In 
VSMC, TH mRNA was qualitatively detectable while DDC mRNA content was too low 
to be detected. No statistically significant regulation of DH and PNMT mRNA content 
was observed after hypoxic exposure in VSMC. This suggests that vascular cells are 
capable of catecholamine synthesis and this synthesis is differentially regulated under 
hypoxic conditions. 
 This is the first study providing evidence of expression of catecholamine 
synthesis enzymes in isolated vascular cells. Previously, Kuncova et al., 2007, had 
shown that the presence of catecholamines in rat aorta and SMA. Chemical 
sympathectomy with the neurotoxin, 6-hydroxydopamine, significantly reduced 
norepinephrine and epinephrine levels, while dopamine content was unaffected. 
Functional studies using rat SMA showed an endothelium-dependent vasodilation in 
response to fall of PO2  -25 mm Hg, which could be blocked by the specific dopamine 
D1 receptor antagonist SCH23990, suggesting possible role of locally produced 
dopamine in the vasodilation.  
 This study suggests that there are two sources of catecholamines, in particular 
dopamine - neuronal and non-neuronal - and the non-neuronal synthesis is carried out 
by both principal cell types of vascular wall, i.e. EC and VSMC. Catecholamines 
produced by vascular cells are released in the event of hypoxia. This locally synthesized 
and released dopamine mediates vasodilation and might help in an increased O2 and 
nutrient supply to the affected organ.  
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VIII Zusamenfassung 
Katecholamine (Dopamine, Noradrenalin und Adrenalin) spielen eine 
physiologisch wichtige Rolle als Neurotransmitter sowie in der Regulation 
verschiedenster Körperfunktionen. Dopamin ist ein Zwischenprodukt in der Synthese 
von Noradrenalin und Adrenalin sowie auch selbst ein Neurotransmitter im zentralen 
Nervensystem. In den systemischen Arterien des Säugers ist Dopamin zumeist ein 
potenter Vasodilatator. Die vaskulären Effekte von Dopamin werden über spezifische G 
Protein-gekoppelte Rezeptoren (D1 - D5) vermittelt.  
In der vorliegenden Studie wurde das Vorkommen der enzymatischen 
Maschinerie zur Katecholaminsynthese (Tyrosinhydroxylase = TH, DOPA-
Decarboxylase = DDC; Dopamin-β-Hydroxylase = DβH, Phenyläthanolamin-N-
Methyltransferase = PNMT) in Arterien der Ratte untersucht sowie auch deren Hypoxie 
abhängige Regulation in Endothel-(EC) und vaskulären glatten Muskelzellen (VSMC). 
Der Gehalt an mRNA wurde über quantitative RT-PCR untersucht, TH-
Proteinexpression wurde mittels Western Blot bestimmt. Weiterhin wurde die 
Expression des geschwindigkeitsbestimmenden Enzyms der Katecholaminsynthese 
(TH) mittels quantitativer RT-PCR, Immunhistochemie und Western Blot in intakten 
Gefäßen (Brustaorta, abdominale Aorta, obere Mesenterialarterie und Femoralarterie) 
untersucht. 
Expression der mRNA für alle vier Enzyme war nachweisbar und wurde in allen 
untersuchten Arterien quantifiziert. Hierbei zeigten sich für die einzelnen Enzyme 
unterschiedliche mRNA-Mengen, wobei PNMT die niedrigste Expression aufwies. TH-
Protein wurde in diesen Arterien immunhistochemisch und im Western Blot 
nachgewiesen. Die TH-Expression in diesen Arterien lässt eine aktive Synthese von 
Dopamin und/oder anderen Katecholaminen erwarten. In einer früheren Arbeit wurde 
TH-mRNA-Expression in der Aorta der Ratte gezeigt und es wurde angenommen, dass 
dies durch eine Kontamination durch Paraganglien während der Probengewinnung 
beruhte. In den immunhistochemischen Untersuchungen in dieser Arbeit waren 
Paraganglien nicht nachweisbar, was darauf hinweist, dass die Aorta selbst zur 
Katecholaminsynthese in der Lage ist. 
EC wurden aus der Aorta und Lungenarterie der Ratte isoliert und kultiviert. Sie 
wurden durch den Nachweis der DiI-Ac-LDL-Aufnahme und durch Immunmarkierung 
mit anti-vWF-Antikörpern charakterisiert. VSMC wurden von der Brust und der 
Abdominalaorta isoliert und kultiviert, ihre Charakterisierung erfolgte durch 
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Immunmarkierung mit anti α-smooth muscle actin Antikörper. Unter normoxischen 
Kulivierungsbedingungen exprimieren EC und VSMC mRNA für alle Enzyme der 
Katecholaminsynthese. Diese Gefäßzellen wurden dann für 6, 12 und 24 Stunden 
hypoxischer (1% O2) Atmosphäre exponiert. Real-time RT-PCR zeigte die mRNA für 
alle oder einen Teil der Enzyme der Katecholaminsynthese in diesen Zellen. In den 
Lungen-EC der Ratte bewirkte Hypoxie-Exposition eine Hochregulation der TH-mRNA 
um das 25-fache nach 24 Stunden und der DβH mRNA um das 8-fache nach 6 und 24 
Stunden, wohingegen DDC- und PNMT-mRNA Gehalt sich nicht signifikant 
veränderten. Im Gegensatz dazu zeigten sich keine signifikanten Veränderungen in 
Aorten-EC der Ratte nach hypoxischer Exposition. In VSMC war TH-mRNA qualitativ 
nachweisbar, wohingegen der DDC-mRNA-Gehalt unter der Nachweisgrenze lag. 
Hypoxie-Exposition der VSMC resultierte nicht in einer statistisch signifikant 
nachweisbaren Regulation des DβH- und PNMT-mRNA-Gehalts. Diese Ergebnisse 
zeigen, dass Zellen der Gefäßwand zur Katecholaminsynthese in der Lage sind und dass 
diese Synthese unter hypoxischen Bedingungen unterschiedlich reguliert wird. 
Dies ist die erste Studie, die einen direkten Nachweis der Expression der 
Katecholaminsynthese-Enzyme in isolierten Gefäßwandzellen liefert. Kuncova und 
Mitarbeiter zeigten zuvor in 2007 das Vorkommen von Katecholaminen in der Aorta 
und oberen Mesenterialarterie der Ratte. Chemische Sympathektomie mit dem 
Neurotoxin 6-Hydroxydopamin führte zu einer signifikanten Reduktion des 
Noradrenalin- und Adrenalingehaltes, während der Dopamingehalt konstant blieb. 
Funktionelle Studien an der oberen Mesenterialarterie der Ratte zeigten eine 
endothelabhängige Vasodilatation bei einem Abfall des PO2 um 25 mmHg, welche 
durch den spezifischen Dopamin D1 Rezeptorantagonisten SCH23990 aufgehoben 
wurde. Dies weist auf eine wahrscheinliche Rolle des lokal produzierten Dopamin in 
der Vasodilatation hin. 
Die Ergebnisse dieser Studie lassen zwei verschiedene Quellen von 
Katecholaminen, insbesondere Dopamin, in der Gefäßwand annehmen – neuronal und 
nicht-neuronal – und die nicht-neuronale Synthese kann von den beiden 
vorherrschenden Zellen der Gefäßwand (EC und VSMC) bewerkstelligt werden. Von 
Gefäßmuskelzellen hergestellte Katecholamine können unter hypoxischen Bedingungen 
freigesetzt werden. Dieses lokal synthetisierte und freigesetzte Dopamin vermittelt 
Gefäßerweiterung und trägt wahrscheinlich zu einer verbesserten Sauerstoff- und 
Nährstoffversorgung der abhängigen Organe bei.   
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